
==== Front
Curr Gastroenterol Rep
Curr Gastroenterol Rep
Current Gastroenterology Reports
1522-8037
1534-312X
Springer US New York

39145848
939
10.1007/s11894-024-00939-3
Article
Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments
http://orcid.org/0000-0001-5645-857X
Scarpignato Carmelo carmelo.scarpignato@unipr.it
carmelo.scarpignato@gmail.com

1234
Hunt Richard H. 5
1 https://ror.org/02k7wn190 grid.10383.39 0000 0004 1758 0937 Department of Medicine & Surgery, University of Parma, Parma, Italy
2 Department of Health Sciences, United Campus of Malta, Msida, Malta
3 https://ror.org/00t33hh48 grid.10784.3a 0000 0004 1937 0482 Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, Hong Kong
4 https://ror.org/03gnr7b55 grid.4817.a 0000 0001 2189 0784 Faculty of Medicine, University of Nantes, Nantes, France
5 https://ror.org/02fa3aq29 grid.25073.33 0000 0004 1936 8227 Department of Medicine, Division of Gastroenterology and Farncombe Family Digestive, Health Research Institute, McMaster University, Hamilton, ON Canada
15 8 2024
15 8 2024
2024
26 11 273293
9 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Purpose of the Review

Acid suppression with proton pump inhibitors (PPIs) represents the standard of care in the treatment of acid-related diseases. However, despite their effectiveness, PPIs display some intrinsic limitations, which underlie the unmet clinical needs that have been identified over the past decades. The aims of this review are to summarize the current status and future development of the new class of antisecretory drugs (potassium-competitive acid blockers, P-CABs) that have recently been introduced into medical practice.

Recent Findings

Over the past decades, clinical needs unmet by the current acid suppressants have been recognized, especially in the management of patients with GERD, Helicobacter pylori infection and NSAID-related peptic ulcer. The failure to address these needs is mainly due to their inability to achieve a consistent acid suppression in all patients and, particularly, to control nighttime acidity. It was then realized that an extended duration of acid suppression would exert additional benefits. The available data with P-CABs show that they are able to address these unmet clinical needs.

Summary

Four different P-CABs (vonoprazan, tegoprazan, fexuprazan and keverprazan) are currently available. However, only two of them are approved outside Asia. Vonoprazan is available in North, Central and South America while tegoprazan is marketed only in Latin American countries. Two other compounds (namely linazapran glurate and zestaprazan) are presently under clinical development. While clinical trials on GERD have been performed with all P-CABs, only vonoprazan and tegoprazan have been investigated as components of Helicobacter pylori eradication regimens. The available data show that—in the above two clinical indications—P-CABs provide similar or better efficacy in comparison with PPIs. Their safety in the short-term overlaps that of PPIs, but data from long-term treatment are needed.

Keywords

GERD
H. pylori Infection
Unmet Clinical Needs
PPIs
P-CABs
Vonoprazan
Tegoprazan
Fexuprazan
Kerverprazan
Linaprazan glurate
Zestaprazan
Università degli Studi di ParmaOpen access funding provided by Università degli Studi di Parma within the CRUI-CARE Agreement.

issue-copyright-statement© Springer Science+Business Media, LLC, part of Springer Nature 2024
==== Body
pmcIntroduction

The past century has been dominated by the Schwartz’ dictum “No acid, no ulcer” [1]. Indeed, the role of acid in the pathophysiology of gastric mucosal lesions represented the impetus guiding research into the treatment of acid-related diseases. Although antacids and anticholinergics were, until the 1970’s, the only medications available, albeit with limited efficacy, it was the discovery of H2-receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) that brought a real breakthrough in the medical management of several acid-peptic conditions, relegating surgery to a very limited role [2]. Now, in the third millennium, acid suppression with delayed release PPIs (DR-PPIs) represents the cornerstone of medical treatment of GERD and its complications [3–5]. However, already 20 years ago it became evident that, despite their efficacy in a majority of patients, PPIs are far from the ideal antisecretory drugs [6, 7]. As a consequence, the search for more effective treatments started looking at new antisecretory drugs, novel formulations as well as fixed drug combinations [8, 9].

Over time, clinical needs unmet by the current acid suppressants have been recognized, especially in the management of patients with GERD, Helicobacter pylori infection and NSAID-related peptic ulcer [6, 10–12]. The failure to address these needs is mainly due to identifiable intrinsic limitations of PPIs, especially their inability to achieve a consistent acid suppression in all patients and, particularly, to control nighttime acidity. It was then realized that an extended duration of acid suppression would exert additional benefits [9, 13, 14]. A number of new drugs and/or drug classes have been developed during the past two decades, including PPIs displaying a half-life longer than that of current ones (the so called third generation PPIs, which however never reached the market) and immediate release or modified release formulations of some currently available compounds (for review see [15]). These new approaches provided a small incremental improvement in the pharmacological control of acid secretion, which was however not sufficient to achieve the degree of control of acidity needed in patients with more complex clinical problems [16].

The true innovation has been the introduction of the of H+,K+-ATPase blockers, called Potassium-Competitive Acid Blockers (P-CABs) [17–19], which share the same target as the PPIs (i.e. the gastric proton pump) but inhibit it through a completely different molecular mechanism. They block the K+ exchange channel of the proton pump, resulting in a very fast, competitive and reversible inhibition of acid secretion. Available P-CABs display a fast and longer-lasting elevation of intra-gastric pH than a DR-PPI. After the introduction in 2015 [20] of the first-in-class successful P-CAB (namely vonoprazan) into the Japanese market, other members of the class have been developed mainly in Asia, and brought also to North America and some Central/South American Countries.

The aims of this review are to summarize the relevant pharmacologic properties and clinical use of P-CABs (in particular those already approved and available for clinical practice) and show how they can, prescribed appropriately, address some of the current unmet clinical needs in acid-related diseases. In addition, those drugs under active clinical development will be discussed.

P-CABs: Chemistry and Pharmacology

Conversely from the current PPIs, which are all substituted benzimidazoles, P-CABs belong to different chemical classes (Table 1). Despite acting through the same mechanism of action, they are therefore heterogeneous molecules. Being all lipophilic, weak bases with high pKa values and stable at low pH, P-CABs concentrate in acidic environments. For instance, a P-CAB displaying a pKa of 6.0 would theoretically have in the parietal cell canaliculus (pH = 1) a concentration 100.000-fold higher than in plasma (pH = 7.4), i.e., 1000 times more than a PPI [21].Table 1 PK and PD characteristics of the currently available P-CABs (at the approved dose), given in fasting conditions, in the morning, to healthy H. pylori-negative Asian subjects

Drug
(Regimen)	Revaprazan
(200 mg daily)	Vonoprazan
(20 mg daily)	Tegoprazan
(50 mg daily)	Fexuprazan
(40 mg daily)	Keverprazan
(20 mg daily)	
Structure	Pyrimidine	SulfonylPyrrole	Benzimidazole	SulfonylPyrrole	SulfonylPyrrole	
Formula	C22H23FN4	C17H16FN3O2S	C20H19F2N3O3	C19 H17F3N2O3S	C22H25FN2O4S	
M.W.	362.44	345.39	387.38	410.41	432.51	
pKa	8.68	9.06	5.1	8.40	9.12	
Tmax, h	2.1 ± 1.3	1.5 (1.5–3.0)	1.0 (0.5–2.0)	2.0 (1.5–4.0)	2.0 (1.2–2.0)	
Half-life, h	2.4 ± 0.2	6.9 ± 1.6	4.1 ± 1.4	9.1 ± 1.2	6.3 ± 1.2	
24 h pH, U—Day 1	2.2	NA	4.1 ± 0.7	3.6 ± 0.9	NA	
24 h pH, U—Day 7	2.5	NA	4.7 ± 1.1	4.2 ± 0.9	NA	
24 h pH > 4 Holding

Time, %—Day 1

	28.1	63.3 ± 17.9	54.5 ± 17.9	44.6 ± 22.9	85.0 ± 3.0	
24 h pH > 4 Holding

Time, %—Day 7

	34.2	83.4 ± 16.7	68.2 ± 24.9	55.7 ± 19.2	98.3 ± 4.3	
NAB Occurrence	Yes	No	No	No	No	
All the studies concerning the different P-CABs (with the exception of kerveprazan) have been performed in Korean or Japanese subjects. Keverprazan was evaluated in healthy Chinese subjects. In the same study the effect of keverprazan was comparable to that of vonoprazan (24 h pH > 4 HTR: 99.4 ± 1.2 and 98.3 ± 4.3 for vonoprazan and keverprazan, respectively). NA = Not Available

The very first P-CABs that have reached clinical trials (i.e., SCH-28080, revaprazan and linaprazan) gave disappointing results. Development of SCH-28080 was stopped because of hepatotoxicity [22] while that of linaprazan (AZD0865) because of failure to show superiority over standard dose PPIs in healing reflux esophagitis [23], and detection of abnormal liver enzymes. However, although unable to achieve better healing of peptic ulcers [24, 25], revaprazan (YH1885) was introduced into the Korean and Indian markets. The development of other molecules (i.e., soraprazan, CS526 and YH-4808) were stopped after phase I or II because their administration was associated with transaminase elevation [26].

Conversely from earlier compounds, current P-CABs (either on the market or under clinical development) are devoid of hepatoxicity and display a more powerful and longer-acting inhibition of the proton pump compared with standard DR-PPIs. These drugs:Are stable in the acidic gastric environment, conversely from PPIs, which are acid-labile drugs. As a consequence, they do not need gastroprotection

Display good solubility both in acidic and neutral conditions

Accumulate into gastric mucosa and concentrate in the secretory canaliculi

Exert a pH-independent and direct inhibitory activity on H+/K+-ATPase, without need for conversion into an active form. They are therefore not pro-drugs

The main pharmacologic differences between P-CABs and PPIs are summarized in Table 2.Table 2 P-CABs and PPIs: Main Differences in the Mechanism of Action (modified from Scarpignato & Hunt [8])

P-CABs	PPIs	
Acts directly (after protonation) on the H+,K+-ATPase enzyme	Requires transformation to the active form, sulphenamide	
Super-concentrates in parietal cell acid space (100.000-fold higher than in plasma)	Concentrate in parietal cell acid space (1000-fold higher than in plasma)	
P-CABs binds competitively to the K+ binding site of to H+,K+-ATPase	Sulphenamide binds covalently to H+,K+-ATPase	
Reversible binding to the proton pump, ionic	Irreversible binding to the proton pump, covalent	
Able to inhibit new proton pumps	Unable to inhibit new proton pumps	
Duration of effect related to half-life of drug in plasma	Duration of effect related to half-life of the sulphenamide-enzyme complex	
Full effect from the first dose	Full effect after repeated doses	

Currently Available P-CABs

Vonoprazan (TAK-438), first introduced in Japan and later in other Asian Countries, has recently been approved by US FDA and is on the market in North America and Central/South American Countries. Being in clinical use for more than 9 years, considerable clinical data have been accumulated and are detailed in several extensive reviews [15, 20, 26–32].

Tegoprazan (formerly RQ-00000004 or CJ-12420) was first introduced in 2019 into the Korean market and then brought to other Asian and Central/South American Countries [33, 34]. Fexuprazan (DPW14012) was approved in Korea in 2021 [35] and keverprazan (H008) received its first approval in China in 2023 [36]. While vonoprazan, keverprazan and fexuprazan are sulphonylpyrrole derivatives, tegoprazan holds the benzimidazole structure (Fig. 1).Fig. 1 P-CABs currently available for clinical practice. Note that vonoprazan, fexuprazan and keverprazan share the sulphonylpyrrole structure while tegoprazan is a benzymidazole derivative. In addition, vonoprazan is given as fumarate whereas keverprazan is a hydrochloride

Vonoprazan: Clinical Pharmacology

PK and PD studies were performed in Japanese and Caucasian healthy male volunteers [37] and showed that vonoprazan displays almost linear pharmacokinetics and a dose-dependent inhibition of acid secretion. Both the 24-h and nocturnal pH > 4 holding times were linearly correlated with AUC [8]. The increase in pH was reflected by an increase in serum gastrin and pepsinogen I concentrations. These pharmacological effects persisted with repeated administration and, after 7 days of treatment, the mean 24-h intragastric pH > 4 holding time with vonozapran 40 mg was 100% in Japanese subjects and 93.2% in UK volunteers; mean nocturnal times spent at pH > 4 were 100% and 90.4%, respectively [38]. In H. pylori-negative healthy volunteers, the increase of intragastric pH with vonozapran (20 mg) was higher and faster compared to lansoprazole (30 mg) and similar to famotidine (20 mg) [39]. Vonoprazan was well tolerated at all doses tested, with no changes in serum transaminase levels.

The antisecretory effect of vonoprazan was quantified in a comprehensive systematic review including 6 study arms and 864 patients (Fig. 2). The analysis showed a linear relationship between drug dose and antisecretory activity [40] thus predicting a dose-dependent therapeutic efficacy in GERD [41].Fig. 2 Antisecretory activity of vonoprazan: dose-related effect, as found in a a systematic review including 6 study arms and 864 patients (from Tansel & Graham [40])

Unlike esomeprazole, the antisecretory activity of vonoprazan was independent of CYP2C19 genotype [42]. In CYP2C19 extensive metabolizers, vonoprazan (20 mg) induced a more rapid and sustained acid inhibitory effect than esomeprazole (20 mg) or rabeprazole (10 mg), and showed virtually no episodes of nocturnal acid breakthrough (NAB) [43]. Therefore, vonoprazan (as well as other members of the P-CAB class) appears to be independent of CYP2C19 polymorphism, providing a similar acid suppression in both Asians and Caucasians. As a consequence, P-CABs overcome the PPI genotype-dependency in both PK and PD (especially for GERD and H. pylori eradication) [4] and allow for a more consistent effect in different patient populations [8].

By using a large data set of available PK studies in healthy volunteers and patients with GERD from Asia and Europe, we developed a population PK model, which was used to evaluate the impact of different covariates, (including race and disease status) on vonoprazan exposure [44]. PK parameters were similar in Asian and non-Asian populations. Variations in weight, age, and race were not predicted to have a clinically relevant impact on vonoprazan exposure or safety and require no changes in vonoprazan dosing. The limited impact of race on exposure suggests that the large body of data on efficacy and safety data for vonoprazan in Asian populations are translatable to non-Asian patients.

A recent crossover study [45] evaluated specifically the food effect on vonoprazan PK, by giving a single 20-mg dose of vonoprazan either following an overnight fast or 30 min after a high-fat breakfast. All the calculated PK parameters in fed and fasted conditions were not significantly different, indicating that vonoprazan can be administered without regard to food intake.

To evaluate the drug-to-drug interaction (DDI) potential of vonoprazan, both in vitro (rat liver microsomes) and in in vivo studies were performed [46]. The results indicated that vonoprazan can inhibit CYP3A4, CYP2C9, CYP2D6, and CYP2B6, suggesting that the co-administration of vonoprazan with cytochrome P450 substrates should be performed cautiously in any clinical setting.

A tiered approach was applied to understand the CYP3A victim and perpetrator DDI potential for vonoprazan [47]. A clinical study was conducted to evaluate the impact of vonoprazan on the exposure of oral midazolam, an index substrate for CYP3A. In addition, a physiologically-based pharmacokinetic (PBPK) model for vonoprazan was developed using all the available in vitro data and in vivo clinical data. The clinical midazolam DDI study indicated weak inhibition of CYP3A, with a less than twofold increase in midazolam exposure. PBPK simulations projected a 50% to 80% reduction in vonoprazan exposure when administered concomitantly with moderate or strong CYP3A inducers. On the contrary, poziotinib (a tyrosine kinase inhibitor employed in HER2 exon 20 mutant Non-Small Cell Lung Cancer, NSCLC), mainly metabolized by CYP3A4, was found to significantly inhibit the metabolism of vonoprazan [48]. Their co-administration should therefore be considered with caution.

Despite weak in vitro activity against CYP2C19, vonoprazan was found to attenuate the antiplatelet function of clopidogrel and prasugel [49]. To better understand the mechanism of this interaction, the effects of vonoprazan in comparison with esomeprazole (well known for its CYP2C19 Inhibitory activity [50]) were evaluated on the pharmacokinetics of a specific CYP2C19 substrate, proguanil [51]. Co-administration of both drugs resulted in increase and decrease in AUC of proguanil and its metabolite (cycloguanil), respectively. Therefore, like esomeprazole, vonoprazan potentially inhibits CYP2C19 at therapeutic doses, suggesting caution in the co-administration of these drugs with CYP2C19 substrates. As a matter of fact, in renal transplant patients vonoprazan co-administration increases tacrolimus concentrations [52]. Thus, frequent monitoring of blood tacrolimus concentration is required when vonoprazan is introduced as an antisecretory compound in the early phase of post-transplantation.

Due to their potent and long-lasting antisecretory activity, covering day and night, P-CABs soon became a component of the currently adopted H. pylori eradication regimens, administered in addition to antimicrobials. It is therefore of importance to know its PK and/or PD interactions with any other drug also used in the treatment of H. pylori infection. Compared with the P-CAB alone, triple therapy with vonoprazan-amoxicillin-clarithromycin increased the AUC0-12h and Cmax of plasma vonoprazan free base (by 1.8-fold), and increased the AUC0-12h and Cmax of plasma clarithromycin (by 1.5 and 1.6-fold, respectively). In contrast, triple therapy with vonoprazan-amoxicillin-metronidazole had no influence on the pharmacokinetics of vonoprazan or metronidazole. The pharmacokinetics of amoxicillin was not influenced by any vonoprazan-based triple therapy [53].

Along the same lines, since acid suppression is an effective gastroprotection in low-dose aspirin (LDA) and NSAID users, understanding of their mutual interaction(s) is of pivotal importance, especially in the elderly. A phase 2, open-label, study [54] evaluated drug-drug interactions between vonoprazan 40 mg and LDA (100 mg) or different NSAIDs [loxoprofen sodium (60 mg), diclofenac sodium (25 mg), or meloxicam (10 mg)] and viceversa. There were few differences in the PK of vonoprazan when administered with LDA or NSAIDs, and few differences in the pharmacokinetics of LDA or NSAIDs when administered with vonoprazan. These differences were small and not clinically relevant. Inhibition of arachidonic acid-induced platelet aggregation by LDA was not influenced by vonoprazan. These results justify gastroprotection with vonoprazan.

Tegoprazan: Clinical Pharmacology

Tegoprazan (formerly RQ-00000004 or CJ-12420) is a benzimidazole derivative with potent and reversible inhibition of K+/H+-ATPAse, endowed with a strong and long-lasting antisecretory activity, which proved to be effective in experimental models of reflux disease and peptic ulcer [55, 56]. The first human study [57] showed that single oral administration of tegoprazan provides rapid elevation of intragastric pH to > 6 under fasted condition in healthy subjects. A subsequent dose-ranging study [58] demonstrated a linear PK profile after single and multiple oral dose administrations and a rapid and dose-dependent acid suppression. Its bioavailability was estimated to be 86–100%. The compound is mostly eliminated through the feces, with renal excretion limited to 3–6% [59]. When single doses of tegoprazan and revaprazan were compared, antisecretory the antisecretory activity of the former was significantly better, with a pH ≥ 4 holding time of 54.5 versus 25.1% achieved by the latter drug. However, the safety parameters (including those concerning liver function) were similar [60].

To improve patient compliance, an orally disintegrating tablet (ODT) of tegoprazan was recently made available. The PK profiles of both conventional tablet and ODT (with or without water) were reported to be equivalent [61]. In addition, a delayed release formulation of tegoprazan was also developed and the PK and PD of various combinations of immediate-release (IR) and delayed-release (DR) formulations carefully studied. The combination of the IR and DR formulation (1:1 ratio) was found to induce stronger gastric acid suppression throughout the day and at night, compared to the conventional IR formulation [62]. When approved, these new formulations will offer clinicians more therapeutic choices.

Two studies [63, 64] evaluated the effect of food on PK and PD of tegoprazan (single oral doses of 50 and 200 mg) and both showed that absorption was delayed under fed condition compared with that of the fasting condition. However, no significant differences were observed in the AUC and 24-h gastric acid suppression, indicating that tegoprazan could be administered regardless of the timing of food consumption and that it displays a meal-independent antisecretory effect. By incorporating in vitro metabolism and absorption profiles together with clinical data, a PK/PD model to predict food effect was developed [65]. Besides fitting the observed post-prandial PK profiles, this model provides a basis for evaluating changes in intragastric pH following tegoprazan administration.

Considering tegoprazan-based triple eradication therapy, a study evaluated the PK and PD of this P-CAB, when co-administered with amoxicillin/clarithromycin in healthy subjects [66]. PK analysis revealed a 2.1-times increase in AUC for both tegoprazan and its M1 active metabolite and the AUC of 14-OH clarithromycin, the antibiotic active metabolite increased 1.8 times while amoxicillin PK was not changed. On days 1 and 7 of treatment, tegoprazan-based regimens (both 50 and 100 mg therapies) maintained pH above 6 for more than 88% of the 24-h period, which was significantly longer when compared with pantoprazole-based therapy [66]. The reciprocal increase in plasma drug concentrations when tegoprazan and clarithromycin are administered in combination was later confirmed and better characterized by another PK study [67].

The DDIs during tegoprazan-based bismuth quadruple therapy can of course be more complex (due to the number of drugs and pills) and have been evaluated in a randomized, multiple-dose, crossover study [68]. The results showed that, while tegoprazan and tetracycline AUC were decreased, the bismuth absorption was increased during combination therapy. The PK of metronidazole was unchanged.

A randomized, multiple-dose, 3-way crossover study [69] evaluated drug-drug interactions between tegoprazan (50 mg once daily) and different NSAIDs [naproxen (500 mg b.i.d.), aceclofenac (100 mg b.i.d) or celecoxib (200 mg b.i.d.)] and viceversa. Both the Cmax and the AUC of naproxen and celecoxib did not change significantly, while the Cmax of aceclofenac increased by some 30%. However, the increase in AUC was very small (albeit significant) with no clinical relevance. On the other hand, NSAIDs did not change tegoprazan PK. These results confirm that gastroprotection with this P-CABs is feasible.

Fexuprazan: Clinical Pharmacology

Fexuprazan (formerly DWP14012) is a sulpholylpyrrole derivative with potent and reversible inhibition of K+/H+-ATPAse, endowed with a more effective, stronger and long-lasting antisecretory activity compared to lansoprazole in several animal models [70] and displaying esophageal and gastric mucosal protection in experimentally-induced reflux disease and peptic ulcer [71]. The first human study was a dose-ranging randomized clinical trial (RCT), performed in healthy male, H. pylori-negative subjects [72]. The PK of fexuprazan after both single and multiple oral doses (20–160 mg) was linear and was not influenced by a high-fat meal. The drug achieved dose-dependent, rapid and sustained suppression of gastric acid secretion throughout the 24 h after single and multiple oral administrations, with the 40 mg and 80 mg doses showing no NAB [72]. Single- and multiple-dose administrations of fexuprazan were generally well tolerated by the subjects. The potential hepatotoxicity of fexuprazan, evaluated with serum levels of liver enzymes, total bilirubin and liver-specific microRNA-122 (miR122) [73], was not higher than that of placebo after multiple oral administrations. No clinically significant abnormalities in liver enzyme and total bilirubin levels were found. In a subsequent study, the PK and PD of fexuprazan were compared among Korean, Caucasian and Japanese healthy subjects [74]. The systemic drug exposure was similar between the three ethnicities after the 40 mg (approved) dose but slightly lower in Caucasian and Japanese subjects after the 80 mg dose. Gastric acid suppression showed a clear exposure–response relationship in all the three ethnicities.

Although the apparent PK of fexuprazan can be described by a simpler, physiologically-based pharmacokinetic (PBPK) models were developed [75, 76], which proved to be capable of effectively simulating the observed data and, by integrating the effects of perpetrator drugs, can be used to predict the impact of drug-to-drug interactions.

With the aim of employing fexuzapran for gastroprotection, a randomized, open-label study evaluated the PK and PD interactions between aspirin (500 mg) and fexuprazan (80 mg) in healthy Koreans [77]. Neither aspirin-induced inhibition of platelet aggregation nor systemic exposure to aspirin were significantly affected by fexuprazan coadministration. The systemic exposure of fexuprazan was decreased up to 20% by aspirin co-administration, but this was not considered clinically relevant.

Keverprazan Clinical Pharmacology

Keverprazan hydrochloride represents the first P-CAB developed in China. Despite preclinical pharmacology data have not yet been published, PK and PD data are available and phase III clinical trials on healing of reflux esophagitis and duodenal ulcer have been performed. The results of these clinical studies allowed the Regulatory Authority to grant it the approval for these indications [36].

The PK study on keverprazan [78] showed quick absorption (with Tmax ranging from 1.25 to3.0 h) and a terminal half-life at steady state of 6.23 and 7.01 h for the 20 and 40 mg dose, respectively. There was no apparent accumulation of keverprazan and the major metabolite after 7-day administration. The drug induced a rapid increase of intragastric pH (reaching pH 4 in about 2 h), which was stable over the 24 h, with a pH ≥ 5 holding time of 97.4% and 100.0% at steady state for the 20 mg and 40 mg dose, respectively. Under the same experimental conditions, the same parameter for vonorazan (20 mg dose) was 99.7%.

Compared with fasting, the mean Cmax and AUC of keverprazan in the fed conditions was increased by 27% and 35%, respectively, showing that drug exposure is increased when it is taken after a high-fat breakfast meal (800–1000 cal, with approximately 50% of total caloric content from fat). There was no obvious food effect on Tmax or half-life [79].

P-CAB Head-to-Head Comparison

As with PPIs, for which only limited head-to-head comparative data exist despite four decades of clinical use, the challenge ahead for newer drugs of this very effective pharmacologic class will be to point out the differential characteristics of each individual drug.

In a recent study [80] the effect of tegoprazan, vonoprazan or esomeprazole on nighttime acid suppression was compared in healthy volunteers, (6 CYP2C19 extensive metabolizers, 5 intermediate metabolizers, 5 poor metabolizers). When administered at bedtime, tegoprazan induced a more rapid inhibition of nocturnal acid secretion compared to vonoprazan or esomperazole. However, over time, vonoprazan produced higher and more sustained elevations of intragastric pH. Both P-CABs showed no NAB (Fig. 3). Furthermore, tegoprazan and vonoprazan effects were independent from CYP2C19 polymorphism [80]. Similar results were obtained when tegoprazan (50, 100 and 200 mg) was compared with dexlansoprazole [81]. A recent network meta-analysis [82], including 55 RCTs and 2015 subjects, compared the efficacy of different antisecretory regimens in preventing NAB. Overall, amongst them (H2RAs, first- and second-generation PPIs, H2RAs at bedtime, novel PPIs and P-CABs) vonoprazan and tegoprazan showed the highest cumulative rank probability (> 90%) of night-time acid suppression.Fig. 3 Effect of evening doses of tegoprazan, vonoprazan or esomeprazole on nocturnal acidity in healthy volunteers (modified from Yang et al., [80])

As for individual members of other drug classes, together with PD, DDI differences are starting to emerge. When atorvastatin was co-administered with vonoprazan, the systemic exposures of atorvastatin and atorvastatin lactone significantly increased while this was not the case for tegoprazan [83]. This difference in behavior has been attributed to the luminal concentrations of vonoprazan (compared to tegopranzan) which were increased enough to inhibit intestinal CYP3A4 and increase the systemic exposure of the orally administered statin.

Since, in both healthy volunteers and patients with GERD, serum gastrin and pepsinogen I levels mirror the antisecretory effect of PPIs and P-CABs [84, 85], hypergastrinemia associated with long-term therapy might cause a concern. This issue was extensively addressed at the Hanbury Manor Workshop in 1995 [86] and there has been no convincing evidence of neoplastic change in the subsequent 30 years of follow up [87]. In most studies of hypergastrinemia associated with the use of antisecretory drugs, gastrin levels do not continue to increase and promptly return to normal after discontinuation of therapy [88]. Despite almost similar antisecretory effect, P-CABs appear to induce a different degree of hypergastrinemia, which is higher for vonoprazan compared to tegoprazan as well as to fexuprazan and zestaprazan [89]. The underlying reasons are not clear at the present time and further data are needed.

Current Clinical Indications of P-CABs

Although vonoprazan was approved in Japan for a wide range of acid-related diseases, including gastric and duodenal ulcer, reflux esophagitis, prevention of LDA and NSAID-associated ulcer and, in combination with antimicrobials, Helicobacter pylori infection and related conditions [20], the most widely accepted clinical use in North and South/Central America are erosive and non-erosive reflux disease as well as H. pylori eradication.

Since all the (approved and potential) vonoprazan indications have been presented in a previous review [15], only GERD and H. pylori infection, will be discussed below.

Vonoprazan Efficacy in GERD

Erosive Reflux Disease

As predicted by a large meta-analysis evaluating the intra-gastric pH data of the currently used antisecretory regimens [41, 90], the healing rate of reflux esophagitis after 8-week therapy with vonoprazan was very high (almost 100% in Asian trials). The large amount of clinical data accumulated have been the subject of some systematic reviews and meta-analyses, providing evidence-based results.

While another meta-analysis is still ongoing [91], a systematic review and meta-analysis [92] including 6 eligible RCTs, comparing the efficacy and safety of vonoprazan with PPIs for GERD, has been published. Results show that vonoprazan is non-inferior to PPIs as therapy for patients with GERD (RR: 1.06 – 95% C.I. 0.99–1.13). However, subgroup analysis indicates that vonoprazan is more effective than PPIs for patients with severe erosive esophagitis (RR: 1.14 – 95% C.I. 1.06–1.22). The safety outcomes for vonoprazan are similar to those for PPIs (RR: 1.08 – 95% C.I. 0.96–1.22). In addition to pairwise comparisons, three network meta-analyses are available [93–95]. The first [93] shows that GERD-healing with vonoprazan is higher than with rabeprazole (20 mg) but not higher than other PPIs. However, subgroup analysis indicates that vonoprazan is more effective than most PPIs for patients with severe erosive esophagitis. This was confirmed by the second, very recent meta-analysis [94], specifically devoted to grade C and D (according to the Los Angeles classification) esophagitis. Based on the failure to achieve mucosal healing, 20 mg of vonoprazan q.d. ranked first among antisecretory drugs in initial and maintained healing of severe mucosal lesions. The superiority of vonoprazan over some PPIs in the maintenance of healing was confirmed also by the third network meta-analysis [95], which however suggested future direct comparisons to confirm this finding.

Two large non-inferiority RCTs [96, 97], not included in the above systematic reviews, have recently been published. One in Asia (predominantly mainland China, Malaysia, South Korea and Taiwan) and one in USA. In the Asian trial [96] vonoprazan 20 mg was shown to be effective and non-inferior to lansoprazole 30 mg in terms of endoscopic reflux esophagitis healing rate at 8 weeks, with slightly higher healing rates of vonoprazan at 2 and 4 weeks. The US trial [97], the first comparing a P-CAB and a PPI in a H. pylori-negative Western population, confirmed that vonoprazan was non-inferior to lansoprazole for healing and maintenance of healing of erosive esophagitis. Furthermore, it showed that this P-CAB achieved higher rates of healing and maintenance of healing than the PPI, with the differences seen primarily in those with more (C and D) severe esophagitis (Fig. 4). In both trials, there was no statistically significant difference in symptom relief between the treatment arms. However, in some studies [98] significantly more patients attained complete nocturnal heartburn relief with vonoprazan than with lansoprazole.Fig. 4 Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: experimental design and results from the US trial [from Laine et al. [97])

By combining the data from the above trial with previous Japanese and European phase 1 studies, we generated a PK/PD model to link vonoprazan exposure to pH holding time and to evaluate the dose-exposure–pH holding time ratios (HTR) relationship [99]. The model, validated by goodness-of-fit plots between predicted and observed pH values, allowed simulations to predict pH HTRs with vonoprazan 20 mg once and twice daily at day 7 and showed that these doses should maintain intragastric pH > 4 for 89.7% and 98.1% of the time, respectively. These data support the use of the above regimens in clinical practice either for GERD or H. pylori infection (see below).

Esophageal mucosal injury is often accompanied by symptoms such as heartburn, regurgitation, sore throat, and swallowing difficulties [100]. Besides healing erosive esophagitis, reflux symptoms should also be managed since they have a detrimental impact on health-related quality of life (HRQoL). Therefore, the appropriate drug able to achieve as quickly as possible complete symptom relief should be selected. Since vonoprozan displays a fast onset of antisecretory activity, it should be expected to provide a similarly fast symptomatic effect. Unfortunately, symptom resolution has only seldom specifically evaluated in clinical trials. A double-blind, placebo controlled, RCT [98] showed that heartburn was relieved sooner with vonoprazan than with lansoprazole (p < 0.05). Heartburn was completely relieved in 31.3% and 12.5% of patients on day 1 with vonoprazan and lansoprazole, respectively. Furthermore, significantly more patients achieved complete nocturnal heartburn relief with vonoprazan than lansoprazole (p < 0.01). Due to lack of head-to-head comparisons (with the exception of this trial), a network meta-analysis [101] was needed to provide an evidence-based evaluation of vonoprazan speed of action. By including 10 RCTs, specifically assessing symptom relief in patients with reflux esophagitis after acid suppression, the analysis found that—for heartburn resolution rate on day 1—vonoprazan (20 mg once daily) was superior to placebo (median odds ratio = 16.75, 95% credible intervals: 2.16–207.80). For heartburn resolution rate on day 7, vonoprazan was superior to placebo and other comparators except rabeprazole (20 mg once daily).

Some small studies have shown that vonoprazan is also effective in patients with PPI-resistant esophagitis. A recent systematic review with meta-analysis [102], which included both observational and clinical studies (N = 12), found the drug effective both in treatment and maintenance of this challenging clinical condition. Healing rates of PPI-resistant erosive esophagitis with vonoprazan 20 mg were 91.7% (95% CI: 86.8–94.8%) and 88.5% (95% CI: 69.7–96.2%) at weeks 4 and 8, respectively. Healing was accompanied by symptom relief in a large proportion (some 75% at week 4) of patients. The 10 mg dose was also effective in maintenance of healing in 86.0% (95% CI 72.1–94.7%) of patients at week 24, and 93.8% (95% CI 69.8–99.8%) at week 48.

Non-erosive Reflux Disease

Several Asian studies (for review see [15]) have shown that, besides in erosive esophagitis, vonoprazan (given daily or on demand) is effective in non-erosive disease (NERD) as well. A recent US trial [103] evaluated the efficacy and safety of different doses of vonoprazan versus placebo for the on-demand treatment of patients with NERD efficacy of different doses (10, 20 and 40 mg) of vonoprazan versus placebo for the on-demand treatment (drug taken in response to heartburn episode) of patients with NERD. All the investigated doses were safe and significantly better than placebo in providing rapid and sustained relief from heartburn episodes, with the 40 mg dose, providing limited extra benefit over the lower doses. Although the primary endpoint was assessed at 3 h, greater improvement in heartburn was already observed within the first hour in the vonoprazan group as compared to the placebo group and occurred within 30 min [104]. Thanks to its favorable PK and PD, preventive consumption 1–2 h before) of vonoprazan may be desired and practiced by some patients who anticipate GERD-related symptoms after a large meal.

It is important to appreciate that P-CAB-resistant NERD has also been reported and ascribed to weakly acidic reflux or much more likely to be functional heartburn [105]. This apparent resistance, however, could be dose-dependent. A retrospective, small study [106] evaluated NERD patients with symptoms resistant to double-dose PPIs, who were switched to vonoprazan (20 mg daily). pH-impedance recording revealed fewer reflux events at pH < 5 in patients with symptom improvement compared to those without. In these patients, the proportion of reflux at pH < 4 decreased but that of reflux at pH 4–5 increased while that of reflux at pH < 5 did not change [106]. Despite the limitations of the study, the results suggest that the lack of symptom improvement may be related to inadequate acid suppression that could be addressed by a higher vonoprazan dose.

Tegoprazan Efficacy in GERD

Erosive Reflux Disease

The first Korean trial [107] demonstrated that tegoprazan, administered at 50 or 100 mg once daily, was non‐inferior to esomeprazole 40 mg in achieving healing rate of erosive esophagitis at both week 4 (90.3% versus 88.5%) and week 8 (99.1% versus 99.1%). Both doses of tegoprazan were highly effective albeit the 100 mg dose provided no additional clinical benefit over 50 mg. The number of patients with C and D esophagitis was too small to allow a subgoup analysis with proper interpretation of results in severe esophageal injury.

Tegoprazan (25 mg daily) was also non inferior to lansoprazole (15 mg daily) for maintaining remission of healed mild esophagitis at 12 and 24 weeks, an efficacy that remained consistent in CYP2C19 extensive metabolizers [108]. The endoscopic remission rate after 24 weeks was 90.6% with tegoprazan and 89.5% with lansoprazole. Tegoprazan was not inferior to lansoprazole also for maintaining endoscopic remission also at 12 weeks.

Non Erosive Disease

Like vonoprazan, tegoprazan was also found to be effective in patients with NERD. Two doses of the P-CAB (50 and 100 mg) were tested and both were found more effective than placebo, with 42.5%, 48.5% and 24.2% of patients in each arm respectively, showing complete resolution of major symptoms (heartburn and regurgitation) at week 4 [109]. The tegoprazan response rate was similar to that observed with PPIs, which are known to be less effective in endoscopy-negative reflux disease due to the complex pathophysiology and heterogeneous population of patients [110].

Fexuprazan Efficacy in GERD

This P-CAB was investigated in a phase 3, multicenter, randomized, double-blind trial. Two hundred and sixty adult patients with endoscopically confirmed erosive esophagitis (LA Grades A to D) were randomized to receive fexuprazan (40 mg once daily) or esomeprazole (40 mg once daily) [111]. The primary outcome measure was the cumulative proportion of patients with healed mucosal breaks, confirmed by endoscopy, at week 8. Healing rate at week 4, symptoms and quality of life were also assessed. Fexuprazan was non-inferior to esomeprazole, with identical (i.e., 99.1%) cumulative healing rates at 8 weeks and similar rates (90.3% and 88.5%, respectively) at 4 weeks. However, fexuprazan showed better symptom relief in patients with moderate to severe heartburn, an effect persisting also during night time. A similar benefit was evident also for cough. The drug was well tolerated, with an incidence of adverse events comparable between treatment groups [111]. Another non-inferiority study with a similar experimental design was performed in China [112]. The healing rates of fexuprazan and esomeprazole groups at 8 weeks were 88.5% and 89.0%, respectively. No significant difference was found between groups in esophagitis healing rates at 4 weeks, as it was in symptom responses and changes of GERD-HRQL. Two additional studies with fexuprazan were presented at the 2023 Digestive Disease Week meeting. The first [113] confirmed that this P-CAB provides the esophagitis healing rate and symptom relief of esomeprazole. In the second study [114], the effect of two different dosing times (before-meal and after meal) of fexuprazan (40 mg once daily) in patients with erosive esophagitis were compared. Healing rates were similar between the two arms at both 2 weeks (95.8% versus 97.1%) and 4 weeks (98.8% versus 100%).

Keverprazan for GERD

A phase III RCT [115], performed in China, compared keverprazan (20 mg once daily) to lansoprazole (30 mg once) for healing erosive esophagitis. This study demonstrated the non-inferior efficacy and safety of keverprazan to lansoprazole. Esophagitis healing rates at 4 and 8 weeks were comparable between the two arms, with healing rates of 95.8% and 89.9%, respectively. However, per protocol analysis showed that the keverprazan group even had a significant higher healing rate at 8 weeks.

P-CABs for GERD: Conclusions

P-CABs clearly overcome many of the drawbacks and limitations of the DR-PPIs. In acid-related disorders, mucosal healing is directly related to the degree and duration of acid suppression and the length of treatment [13, 41]. Considering the difficulties encountered in achieving effective symptomatic control, particularly at night, using currently available DR-PPIs once daily, this new class of drugs achieves rapid, potent and prolonged acid suppression and offers the chance of addressing some of the unmet clinical needs in GERD [6, 10, 11, 13], such as the need for fast and assured healing of severe reflux esophagitis and achieving rapid heartburn relief.

We have recently developed a mathematical (non-linear, mixed-effects) model to examine the relationship between pH holding HTRs and erosive esophagitis healing rates with all the three classes of antisecretory drugs (H2RAs, PPIs and P-CABs) [116]. Data from 82 papers, reporting mean pH > 4 HTRs at steady state, and 104 clinical trials with esophagitis healing rates, were included in the analysis. The final model well described the available data and the correlation between observed and predicted healing rates was excellent. By using this model, we were able to calculate the probability to achieve a target healing rate by the different classes of antisecretory drugs. The results show clearly that – whatever the selected target – P-CABs appear the most effective drugs for healing reflux esophagitis (Fig. 5).Fig. 5 Probability to achieve a target healing rate by the different classes of antisecretory drugs (from Howden et al. [116])

On the basis of their superior efficacy, P-CAB treatment is now suggested for healing of mucosal lesions by the most recent Asian guidelines on GERD (the Seoul Consensus [117], the Chinese Expert Consensus [118], the Japanese Guidelines [119]) and by the very recent Mexican Clinical Practice Recommendations [120] and will surely be included in the future recommendations from the Western GI Societies.

P-CABs for the Treatment of H. pylori Infection

Currently PPIs are an essential component of any H. pylori eradication regimen [121]. To be most effective, full dose PPIs should be given twice daily, concomitantly with antimicrobials since the mean cure rates are greater in patients who use high-dose PPI, compared with the standard-dose regimen [4]. The importance of the degree of acid suppression on the eradication efficacy became apparent when attempting to validate a dual (namely omeprazole-amoxicillin combination) therapy. Indeed, a linear relationship between omeprazole dose (20–120 mg daily) and eradication rate was clearly evident: the greater acid suppression, the higher eradication rate [122].

Prolonged acid suppression especially during the night, is crucial for H. pylori eradication [123, 124]. Moreover, it was clear that the eradication rate was higher in those without nocturnal acid breakthrough (NAB) than in NAB-positive patients [123]. As a consequence, antisecretory drugs, which offer superior control of both day and night-time acidity, should represent a better choice for H. pylori eradication regimens.

Vonoprazan-based Eradication Regimens

A large amount of data on the use of vonoprazan as a component of different eradication regimens have now been accumulated from studies in Japan and other Asian Countries. Only recently has the drug been investigated in US and European patients.

In contrast to PPIs [4], which display a direct antimicrobial activity against H. pylori, vonoprazan (as well as tegoprazan) do not inhibit the growth of the microorganism [125]. However, the minimal inhibitory concentrations (MICs) of clarithromycin, fluoroquinolone, metronidazole, and amoxicillin against resistant H. pylori isolates improved after tegoprazan administration. The proportion of strains affected varied from 35 to 56%, depending on the given antimicrobial.

The better efficacy of vonoprazan-based, over PPI-based triple (and, more recently, quadruple) regimens – as first line therapy—has been emphasized by several meta-analyses [126–130]. In addition, a systematic review of second line treatments [131] showed that vonoprazan-based regimens still provide significantly higher eradication rates compared to PPI-based regimens. Moreover, an additional meta-analysis [132] found that vonoprazan is superior to conventional PPIs only for eradication of clarithromycin-resistant H. pylori strains while vonoprazan-based and conventional PPI-based therapies are similarly effective in patients harboring clarithromycin-susceptible H. pylori strains. Finally, an interesting, albeit retrospective, study [133] found that vonoprazan-based triple therapy is effective as susceptibility-guided triple therapy for H. pylori eradication.

After the original report of Miehlke et al. [122], several investigators studied both standard- and high-dose PPI combinations with amoxicillin in the hope of finding an effective and simple eradication regimen. While the standard dose PPI-amoxicillin dual therapy gave disappointing eradication rates (for review see [134]), stronger and long-lasting acid suppression appeared to be successful. Nine meta-analyses [135–143] collected all the studies with high-dose PPI-amoxicillin combinations, which showed that this dual therapy is as effective as triple or bismuth-based quadruple therapy, either in first-line or rescue treatment. In addition, compliance with dual therapy was in some analyses better and the adverse event rate always lower [135–137].

The antisecretory effect of vonoprazan is long-lasting (covering both daytime and nighttime). A twice daily dose could therefore be sufficient to synergize with amoxicillin, thus further enhancing compliance with respect to the high-dose PPI regimens. As attested by 6 different meta-analyses [144–149], the eradication rate of vonoprazan-amoxicillin dual therapy was significantly higher than that of PPI-triple therapies. However, when this dual therapy was compared to bismuth-based quadruple therapy, two very recent meta-analyses provided different results According to the first [150], the cure rate of both regimens was similar while the second one [149] found a lower efficacy with dual therapy. Nevertheless, both studies pointed out that the rate of adverse effects of the dual therapies was significantly lower than the triple.

Together with pairwise meta-analyses, a large network meta-analysis, including 68 RCTs giving a total of 92 paired comparisons with 22.975 patients randomized to 8 first-line regimens, was performed by a group of European leading investigators [151]. The overall results showed that only vonoprazan triple therapy achieved cure rates of > 90%. Furthermore, the comparative effectiveness ranking showed that vonoprazan triple therapy gave the best results, whereas standard triple therapy was the least efficacious regimen. A more recent, network meta-analysis [152], including 101 Chinese trials involving 21.745 patients, found that the efficacy of vonoprazan-bismuth–containing quadruple therapy ranked first, followed by high-dose vonoprazan-amoxicillin dual therapy.

The first vonoprazan study for H. pylori eradication in the Western world was performed in Australia [153] by Borody’s Team, who evaluated eleven different antimicrobial combinations. These included different antibiotics (mainly amoxicillin, rifabutin and tetracycline) as well as levofloxacin, furazolidone, nitazoxanide They treated 153 patients, 31% of whom had previously failed eradication attempts with a PPI-based triple therapy. In patients treated for the first time, eradication was achieved in 100% of cases and in those, who had failed prior, non-vonoprazan-containing treatments, eradication was achieved in 91% of patients.

A large, multicenter, RCT [154] assessed the efficacy of vonoprazan triple and dual therapy for H. pylori infection in the United States and Europe. A total of 1046 treatment-naïve, infected adults were randomized 1:1:1 to open-label vonoprazan dual therapy (20 mg vonoprazan twice daily; 1 g amoxicillin 3 times daily), or double-blind triple therapy twice a day (vonoprazan 20 mg or lansoprazole 30 mg; amoxicillin 1 g; clarithromycin 500 mg) for 14 days. Among patients from the United States and Europe, vonoprazan-based triple and dual regimens were non-inferior to lansoprazole-based triple therapy for eradication of H. pylori strains not resistant to clarithromycin and amoxicillin. In secondary analyses, vonoprazan triple and dual regimens achieved significantly higher eradication rates in the subgroup with clarithromycin-resistant strains and in the overall study population (Fig. 6). These findings were confirmed by the most recent meta-analysis, including 13 studies [155]: the overall efficacy of vonoprazan based therapy was superior to PPI-based therapy (RR: 1.09, 95% CI 1.03 to 1.05, p < 0.01). The same holds true in patients with clarithromycin-resistant strains (RR 1.64, 95% CI 1.21 to 2.23, p < 0.01).Fig. 6 H. pylori eradication rates with vonoprazan-based therapies. Secondary outccomes from the US and European Trial (from Chey et al. [154])

Despite the cure rate of vonoprazan-amoxicillin combination was lower in Caucasian compared to Asian patients, dual therapy may become a simple, first-line regimen for the eradication of H. pylori infection. Before being widely adopted, this dual therapy should be optimized, by selecting the best dose, number of drug administrations and duration [29]. There are indeed sufficient data to prove that optimized vonoprazan-amoxicillin dual therapy can reliably achieve cure rates ≥ 95% [156].+

Antimicrobials have a detrimental effect on gut microbiota [157] and H. pylori eradication regimens make no exception [158]. In this connection, the dual amoxicillin therapy appears to have a minimal impact on the microbiota. Indeed, in contrast to vonoprazan-triple therapy, the alfa-diversity at 1 and 8 weeks did not change significantly compared with baseline [159].

In 2017 WHO listed Helicobacter pylori among 16 antibiotic-resistant bacteria that pose the greatest global threat to human health [160]. Given the alarmingly high H. pylori antibiotic resistance rates, antibiotic stewardship programmes need to be developed and implemented. In this regard, a move to dual therapies – by using only one antibiotic – will fit well to support this endeavor.

Tegoprazan-based Eradication Regimes

On the basis of in vitro data [125] and of the vonoprazan experience (see above), tegoprazan (50 mg b.i.d.) was adopted as the antisecretory component of triple or quadruple therapies and compared with the PPI-based same regimens.

A large, RCT [161] evaluated tegoprazan-based classic 7-day triple therapy (with amoxicillin and clarithromycin) in comparison to the same lansoprazole-based combination. The H. pylori eradication rates were 62.7% and 60.6%, respectively. Subgroup analyses according to MICs or CYP2C19 did not show remarkable differences in eradication rate. A real-world study [162] reported overlapping results (eradication rate of 63.9%), which improved to 78.6% cure rate when extending the tegoprazan-triple therapy to 14 days. When an IR formulation of esomeprazole was used instead of lansoprazole, the eradication rate was similar to that found with tegoprazan-based regimen (78.6% versus 81.4%). These results were replicated in a study comparing tegoprazan- versus rabeprazole-based triple therapy (76.7% versus 75.4%, respectively) [163].

In an attempt to increase the efficacy of the above eradication regimes, bismuth subcitrate was added to both tegoprazan-based and lansoprazole-based 7-day triple therapy [164]. The corresponding eradication rates were 78.8% and 74.5%. A subsequent trial compared tegoprazan therapy, with and without addition of bismuth, showing that Bi-based therapy is significantly more effective (eradication rate: 82.9% versus 71.8%, p = 0.0029) [165].

Tegoprazan was also tested with the classic bismuth quadruple therapy (PPI + tetracycline + metronidazole + bismuth subcitrate) or concomitant therapy (PPI + amoxicillin + clarithromycin + metronidazole). When compared to a lansoprazole-based bismuth regimen, the tegoprazan-based therapy achieved a similar eradication rate (80% versus 77.4%) [166]. Ten-day tegoprazan-based concomitant therapy gave an eradication rate of 90.5% [167], which was not improved by extending the treatment at 14 days [168].

Despite tegoprazan-containing therapies meeting the criteria for non-inferiority to PPI-based therapies, they did not achieve the clinically acceptable cure rate of ≥ 95% or even conditionally acceptable threshold of 90–94% [169]. It should be appreciated, however, that all these studies have been performed in South Korea, where antimicrobial resistance and multidrug resistance are relatively high and still increasing [170, 171].

P-CABs for the Treatment of H. pylori Infection: Conclusions

The distinctive PK and PD properties of P-CABs make them the antisecretory drugs of choice as the component of eradication regimens. In particular, they induce an increase of intragastric pH, which is greater and longer-lasting when compared with PPIs. This allows the microorganism to reach the growth phase, becoming more sensitive to antibiotics (such as amoxicillin and clarithromycin) and improves their intragastric stability and antibacterial efficacy [4].

Antimicrobial resistance is increasing worldwide and remains an important clinical challenge [172]. Vonoprazan use was already discussed in 2016 in the Toronto Consensus [173] and—based on the available data—the Maastricht VI/Florence consensus report [174] stated that “P-CAB-antimicrobial combination treatments are superior, or not inferior, to conventional PPI-based triple therapies for first-line and second-line treatment, and superior in patients with evidence of antimicrobial resistant infections” and suggested P-CAB use as component of dual, triple and quadruple therapies, where available.

P-CABs in Clinical Development

Linaprazan Glurate (X842) is a pro-drug of linaprazan, developed in Europe by Cinclus Pharma AG. The active metabolite has a comprehensive data base from 25 Phase I studies, including more than 600 subjects, and 2 Phase II studies, including 2.973 patients. All these investigations showed linaprazan was well tolerated, with a fast onset of action and full effect from the first dose. However, linaprazan did not control 24 h intragastric pH, likely because of its short plasma half-life [175]. In contrast, linaprazan glurate has a longer half-life which provides effective 24 h pH control.

The first human study of X842 [176] evaluated the PK and PD after single and multiple ascending doses. Linaprazan rapidly appeared in plasma, with the Cmax at ~ 2 h after oral administration. Plasma half-life was ≥ 10 h, following doses of 1 mg/kg or higher. Linaprazan AUC linearly correlated with the X842 dose, with a dose-dependent acid inhibition over the 24 h, and linear correlation between plasma concentrations of the active metabolite (i.e., linaprazan) and intragastric pH. At doses of 2 mg/kg, X842 achieved effective acid control over 24 h without evidence of NAB.

A phase 2, double-blind RCT [177] evaluated a dose-ranging (25–50-75 100 mg twice daily) healing effect of A/B and C/D erosive esophagitis in comparison with lansoprazole (30 mg once daily). The global healing rate for patients with A/B esophagitis was 83.8% and 81.0%, respectively. However, the healing rate for severe (C/D) esophagitis was fairly different, being 73.6% for linaprazan glurate and 37.5% for lansoprazole. The highest healing rate was seen with 75 mg dose that will likely be selected for phase III clinical trials. The drug was well tolerated with no dose-related increase in adverse effects, and the safety profile was comparable to that of lansoprazole [178].

The last P-CAB reaching clinical trials is zastaprazan (JP-1366, under development by Onconic Therapeutics in South Korea), a potent, competitive and highly selective inhibitor of H+/K+ ATPase, endowed with an effective and long-lasting antisecretory activity in several animal models and displaying esophageal and gastric mucosal protection in experimentally-induced reflux disease and peptic ulcer [179]. When compared, under the same experimental conditions, with vonoprazan, it appeared to be about 2.5 more potent. Furthermore, zastaprazan showed a faster onset of action.

The first human study was a dose-ranging RCT, performed in healthy male, H. pylori-negative Korean subjects [180]. The PK of zastaprazan after both single and multiple oral doses (20–160 mg) was linear and was not influenced by a high-fat meal. The drug achieved dose-dependent, rapid and sustained suppression of gastric acid secretion throughout the 24 h after single and multiple oral administrations, with the 20, 40 and 60 mg doses showing no NAB. Administration of zastaprazan after a high-fat meal decreased the peak plasma level while the overall systemic exposure of zastaprazan increased compared to those in the fasted state. The drug was well tolerated with no clinically significant changes in safety and tolerability assessments, with no appreciable changes in the liver function. The serum liver transaminases and fold change of miR-122 after single and multiple administrations of zastaprazan remained within the reference range and were not higher than that of the placebo [180].

Conclusions and Future Perspectives

Effective control of intragastric acidity is crucial for the treatment of acid-related disorders including erosive esophagitis [41, 90, 116]. Although PPIs have been long considered the mainstay of treatment for erosive and non-erosive GERD, not all patients achieve healing of erosive esophagitis with a standard 8-week course and fewer actually achieve satisfactory symptom control. In addition, some patients will have relapse of esophageal lesions despite continuous once-daily maintenance treatment with a PPI. Since PPIs are usually dosed in the morning, many patients will show NAB that is often associated with nocturnal heartburn and poorer clinical outcomes [6, 10, 11].

Intragastric pH must also be effectively controlled for successful eradication of H. pylori infection [121, 181]. While a pH ≥ 7 is not pharmacologically achievable in the human stomach, prolonged duration of an intragastric pH > 6 is likely to be important for the eradication of the infection. A cut-off of an average intragastric pH of 6 across 24 h predicts successful eradication [124]. After the introduction of PPI-based triple therapies in the early ‘90s there has been a slow progress to optimizing eradication regimens with antisecretory drugs. Indeed, despite the advent of sequential, quadruple, concomitant and hybrid therapies, control of intragastric acidity remained suboptimal.

The distinctive pharmacological properties of P-CABs, described above, offered the chance of addressing many of the unmet needs in GERD and H. pylori infection [13, 16]. And indeed, this new class of antisecretory drugs has shown to be successful in these two clinical conditions that are now considered established indications [15].

Being a pH-dependent phenomenon [182], NSAID-gastropathy is effectively prevented by P-CABs [183–185], but their superiority over DR-PPIs has not been demonstrated in this clinical setting. However, based on the available evidence, also secondary prevention of NSAID-gastropathy can be considered an established indication (Table 3).Table 3 Clinical indications (established, potential and under evaluation) of P-CABs

Indications	Superiority
over PPIs	
Established	
  Severe (Los Angeles C & D) reflux esophagitis	Yes	
  Reflux (Los Angeles A & B) esophagitis	No	
  Eradication of the H. pylori infection	Yes	
  Secondary prevention of NSAID-gastropathy	No	
  Non erosive reflux disease	Possible	
Under Evaluation	
  Eosinophilic esophagitis	Likely No	
  Treatment of NSAID ulcer	Likely No	
  Idiopathic peptic ulcer	Likely Yes	
  Prevention of ESD delayed rebleeding	Likely Yes	
Potential	
  Treatment of upper GI (non-variceal) bleeding and prevention of rebleeding	Likely Yes	
The relative efficacy of P-CABs is based on the current available evidence (meta-analyses, RCTs, observation studies and case reports), discussed in this review

Other uses (e.g., peptic ulcer, endoscopic mucosal dissection-induced ulcer, functional dyspepsia) of this class of drugs are being evaluated [15, 186, 187], but clinical data are not yet sufficient to allow a definitive answer on its efficacy and eventual superiority over our current standard of care (i.e., PPIs). The most important indication of upper GI (non-variceal) bleeding, where P-CABs are likely to outweigh the benefits of DR-PPIs, has not yet been explored (Table 3).

Hopefully, these will be fully evaluated also in Europe and North America (vonoprazan has recently been approved by the US FDA), where the choice of antisecretory treatments remains limited. Only after worldwide extensive use can a critical evaluation of a new agent (especially belonging to a new drug class) be made, allowing clinicians to determine whether it is effective and safe and whether it is really superior to currently available treatments. Together with efficacy, also safety data are accumulating, in particular for vonoprazan, now in clinical use for more than 9 years. In a comprehensive systematic review of 77 studies [188], the incidences of any adverse effects AEs, drug-related AEs, serious AEs and AEs leading to drug discontinuation were not significantly different between patients taking vonoprazan and PPIs. However, since the incidence of AEs was higher in patients taking long-term use of vonoprazan than those taking short-term use of vonoprazan [188], data from studies from patients taking the drug from maintenance of reflux esophagitis are awaited with interest. However, the data from the VISION trial [189] concerning patients treated for 260 weeks with vonoprazan are reassuring.

As with every new drug, overuse and misuse can occur and can be avoided only with responsible marketing and thoughtful prescribing, together with careful monitoring of patients treated. At the present time, the indications for treatment with P-CABs should be for the difficult to treat acid-related disorders and unmet needs, where the benefit to risk is expected to be most favorable [15, 17].

Author Contributions

Professor Scarpignato and Professor Hunt agreed to write the review and constructed an outline for the article. Professor Scarpignato performed a literature search and prepared the first draft. Professor Hunt contributed to all the sections of the manuscript, edited and commented on the first draft and subsequent revisions. All authors have approved the final version of the article and the order of authorship.

Funding

Open access funding provided by Università degli Studi di Parma within the CRUI-CARE Agreement.

Data Availability

No datasets were generated or analysed during the current study.

Declarations

Competing Interests

Professor Scarpignato is member of the Advisory Board of Phathom and Professor Hunt is member of the Advisory Board of Cinclus. The first Company developed and is marketing a P-CAB (vonoprazan) in the US, while the second one is developing another P-CAB (namely Linaprazan glurate).

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Fatović-Ferenčić S Banić M No acid, no ulcer: Dragutin (Carl) Schwarz (1868–1917), the man ahead of his time Dig Dis 2011 29 5 507 510 10.1159/000334384 22095019
Fatović-Ferenčić S, Banić M. No acid, no ulcer: Dragutin (Carl) Schwarz (1868–1917), the man ahead of his time. Dig Dis. 2011;29(5):507–10. 10.1159/000334384.22095019 10.1159/000334384
2. Díaz-Rubio M Historical perspective of gastric acid inhibition Drugs 2005 65 Suppl 1 1 6 10.2165/00003495-200565001-00002 16335852
Díaz-Rubio M. Historical perspective of gastric acid inhibition. Drugs. 2005;65(Suppl 1):1–6. 10.2165/00003495-200565001-00002.16335852 10.2165/00003495-200565001-00002
3. Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD: an overview of their pharmacology, efficacy and safety. Pharmacol Res. 2009;59(3):135–53. 10.1016/j.phrs.2008.09.016.
4. Scarpignato C Gatta L Zullo A Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression BMC Med 2016 14 1 179 10.1186/s12916-016-0718-z 27825371
Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179. 10.1186/s12916-016-0718-z.27825371 10.1186/s12916-016-0718-z
5. Scarpignato C, Gatta L. Acid suppression for management of gastroesophageal reflux disease: benefits and risks. In: Morice A, Dettmar P (eds) Reflux Aspiration and Lung Disease, Springer International Publishing AG, Cham 2018;269–291. 10.1007/978-3-319-90525-9_23.
6. Hunt RH Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005 Aliment Pharmacol Ther 2005 22 Suppl 3 10 19 10.1111/j.1365-2036.2005.02715.x 16303032
Hunt RH. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther. 2005;22(Suppl 3):10–9. 10.1111/j.1365-2036.2005.02715.x.16303032 10.1111/j.1365-2036.2005.02715.x
7. Tytgat GN Shortcomings of the first-generation proton pump inhibitors Eur J Gastroenterol Hepatol 2001 13 Suppl 1 S29 33 11430506
Tytgat GN. Shortcomings of the first-generation proton pump inhibitors. Eur J Gastroenterol Hepatol. 2001;13(Suppl 1):S29-33.11430506
8. Scarpignato C Hunt RH The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease Curr Opin Gastroenterol 2019 35 4 344 355 10.1097/MOG.0000000000000543 31045597
Scarpignato C, Hunt RH. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Curr Opin Gastroenterol. 2019;35(4):344–55. 10.1097/MOG.0000000000000543.31045597 10.1097/MOG.0000000000000543
9. Scarpignato C Hunt RH Proton pump inhibitors: the beginning of the end or the end of the beginning? Curr Opin Pharmacol 2008 8 6 677 684 10.1016/j.coph.2008.09.004 18840545
Scarpignato C, Hunt RH. Proton pump inhibitors: the beginning of the end or the end of the beginning? Curr Opin Pharmacol. 2008;8(6):677–84. 10.1016/j.coph.2008.09.004.18840545 10.1016/j.coph.2008.09.004
10. Dickman R Maradey-Romero C Gingold-Belfer R Unmet needs in the treatment of gastroesophageal reflux disease J Neurogastroenterol Motil 2015 21 3 309 319 10.5056/jnm15105 26130628
Dickman R, Maradey-Romero C, Gingold-Belfer R, et al. Unmet needs in the treatment of gastroesophageal reflux disease. J Neurogastroenterol Motil. 2015;21(3):309–19. 10.5056/jnm15105.26130628 10.5056/jnm15105
11. Katz PO Scheiman JM Barkun AN Review article: acid-related disease-what are the unmet clinical needs? Aliment Pharmacol Ther 2006 23 Suppl 2 9 22 10.1111/j.1365-2036.2006.02944.x 16700899
Katz PO, Scheiman JM, Barkun AN. Review article: acid-related disease-what are the unmet clinical needs? Aliment Pharmacol Ther. 2006;23(Suppl 2):9–22. 10.1111/j.1365-2036.2006.02944.x.16700899 10.1111/j.1365-2036.2006.02944.x
12. Scheiman JM. Unmet needs in non-steroidal anti-inflammatory drug-induced upper gastrointestinal diseases. Drugs. 2006;66(1):15–21. 10.2165/00003495-200666001-00004.
13. Scarpignato C Pelosini I Review article: the opportunities and benefits of extended acid suppression Aliment Pharmacol Ther 2006 23 Suppl 2 23 34 10.1111/j.1365-2036.2006.02945.x 16700900
Scarpignato C, Pelosini I. Review article: the opportunities and benefits of extended acid suppression. Aliment Pharmacol Ther. 2006;23(Suppl 2):23–34. 10.1111/j.1365-2036.2006.02945.x.16700900 10.1111/j.1365-2036.2006.02945.x
14. Hunt R Acid suppression for reflux disease: "off-the-peg" or a tailored approach? Clin Gastroenterol Hepatol 2012 10 3 210 213 10.1016/j.cgh.2011.11.018 22138274
Hunt R. Acid suppression for reflux disease: “off-the-peg” or a tailored approach? Clin Gastroenterol Hepatol. 2012;10(3):210–3. 10.1016/j.cgh.2011.11.018.22138274 10.1016/j.cgh.2011.11.018
15. Scarpignato C Hunt RH Acid suppressant therapy: a step forward with potassium-competitive acid blockers Curr Treat Options Gastroenterol 2021 19 1 94 132 10.1007/s11938-020-00330-x
Scarpignato C, Hunt RH. Acid suppressant therapy: a step forward with potassium-competitive acid blockers. Curr Treat Options Gastroenterol. 2021;19(1):94–132. 10.1007/s11938-020-00330-x.10.1007/s11938-020-00330-x
16. Hunt RH Scarpignato C Potassium-competitive acid blockers (P-CABs): are they finally ready for prime time in acid-related disease? Clin Transl Gastroenterol 2015 6 10 e119 10.1038/ctg.2015.39 26513137
Hunt RH, Scarpignato C. Potassium-competitive acid blockers (P-CABs): are they finally ready for prime time in acid-related disease? Clin Transl Gastroenterol. 2015;6(10):e119. 10.1038/ctg.2015.39.26513137 10.1038/ctg.2015.39
17. Scarpignato C Hunt RH Editorial: towards extended acid suppression-the search continues Aliment Pharmacol Ther 2015 42 8 1027 1029 10.1111/apt.13384 26374257
Scarpignato C, Hunt RH. Editorial: towards extended acid suppression-the search continues. Aliment Pharmacol Ther. 2015;42(8):1027–9. 10.1111/apt.13384.26374257 10.1111/apt.13384
18. Inatomi N Matsukawa J Sakurai Y Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases Pharmacol Ther 2016 168 12 22 10.1016/j.pharmthera.2016.08.001 27514776
Inatomi N, Matsukawa J, Sakurai Y, et al. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases. Pharmacol Ther. 2016;168:12–22. 10.1016/j.pharmthera.2016.08.001.27514776 10.1016/j.pharmthera.2016.08.001
19. Oshima T Miwa H Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases J Neurogastroenterol Motil 2018 24 3 334 344 10.5056/jnm18029 29739175
Oshima T, Miwa H. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil. 2018;24(3):334–44. 10.5056/jnm18029.29739175 10.5056/jnm18029
20. Garnock-Jones KP Vonoprazan: first global approval Drugs 2015 75 4 439 443 10.1007/s40265-015-0368-z 25744862
Garnock-Jones KP. Vonoprazan: first global approval. Drugs. 2015;75(4):439–43. 10.1007/s40265-015-0368-z.25744862 10.1007/s40265-015-0368-z
21. Scarpignato C Pelosini I Di Mario F Acid suppression therapy: where do we go from here? Dig Dis 2006 24 1–2 11 46 10.1159/000091298 16699262
Scarpignato C, Pelosini I, Di Mario F. Acid suppression therapy: where do we go from here? Dig Dis. 2006;24(1–2):11–46. 10.1159/000091298.16699262 10.1159/000091298
22. Andersson K Carlsson E Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases Pharmacol Ther 2005 108 3 294 307 10.1016/j.pharmthera.2005.05.005 16000224
Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther. 2005;108(3):294–307. 10.1016/j.pharmthera.2005.05.005.16000224 10.1016/j.pharmthera.2005.05.005
23. Kahrilas PJ Dent J Lauritsen K A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis Clin Gastroenterol Hepatol 2007 5 12 1385 1391 10.1016/j.cgh.2007.08.014 17950677
Kahrilas PJ, Dent J, Lauritsen K, et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol. 2007;5(12):1385–91. 10.1016/j.cgh.2007.08.014.17950677 10.1016/j.cgh.2007.08.014
24. Chang R Chung IS Park S-H Phase III clinical trial of revaprazan (Revanex®) for gastric ulcer Korean J Gastrointest Endosc 2007 34 6 312 319
Chang R, Chung IS, Park S-H, et al. Phase III clinical trial of revaprazan (Revanex®) for gastric ulcer. Korean J Gastrointest Endosc. 2007;34(6):312–9.
25. Chung IS Choi MG Park S-H Revaprazan (Revanex®), a novel acid pump antagonist, for duodenal ulcer: results of a double-blind, randomized, parallel, multi-center phase III clinical trial Korean J Gastrointest Endosc 2005 31 1 17 24
Chung IS, Choi MG, Park S-H, et al. Revaprazan (Revanex®), a novel acid pump antagonist, for duodenal ulcer: results of a double-blind, randomized, parallel, multi-center phase III clinical trial. Korean J Gastrointest Endosc. 2005;31(1):17–24.
26. Hunt RH, Scarpignato C. Potent acid suppression with PPIs and P-CABs: what’s new? Curr Treat Options Gastroenterol. 2018;16(4):570–90. 10.1007/-018-0206-y.
27. Sugano K Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date Therap Adv Gastroenterol 2018 11 1756283X17745776 10.1177/1756283X17745776 29383028
Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol. 2018;11:1756283X17745776. 10.1177/1756283X17745776.29383028 10.1177/1756283X17745776
28. Yang X Li Y Sun Y Vonoprazan: a novel and potent alternative in the treatment of acid-related diseases Dig Dis Sci 2018 63 2 302 311 10.1007/s10620-017-4866-6 29282636
Yang X, Li Y, Sun Y, et al. Vonoprazan: a novel and potent alternative in the treatment of acid-related diseases. Dig Dis Sci. 2018;63(2):302–11. 10.1007/s10620-017-4866-6.29282636 10.1007/s10620-017-4866-6
29. Graham DY Dore MP Update on the use of vonoprazan: a competitive acid blocker Gastroenterology 2018 154 3 462 466 10.1053/j.gastro.2018.01.018 29337157
Graham DY, Dore MP. Update on the use of vonoprazan: a competitive acid blocker. Gastroenterology. 2018;154(3):462–6. 10.1053/j.gastro.2018.01.018.29337157 10.1053/j.gastro.2018.01.018
30. Echizen H The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations Clin Pharmacokinet 2016 55 4 409 418 10.1007/s40262-015-0326-7 26369775
Echizen H. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2016;55(4):409–18. 10.1007/s40262-015-0326-7.26369775 10.1007/s40262-015-0326-7
31. Otake K Sakurai Y Nishida H Characteristics of the novel potassium-competitive acid blocker vonoprazan fumarate (TAK-438) Adv Ther 2016 33 7 1140 1157 10.1007/s12325-016-0345-2 27287852
Otake K, Sakurai Y, Nishida H, et al. Characteristics of the novel potassium-competitive acid blocker vonoprazan fumarate (TAK-438). Adv Ther. 2016;33(7):1140–57. 10.1007/s12325-016-0345-2.27287852 10.1007/s12325-016-0345-2
32. Martinucci I Blandizzi C Bodini G Vonoprazan fumarate for the management of acid-related diseases Expert Opin Pharmacother 2017 18 11 1145 1152 10.1080/14656566.2017.1346087 28657473
Martinucci I, Blandizzi C, Bodini G, et al. Vonoprazan fumarate for the management of acid-related diseases. Expert Opin Pharmacother. 2017;18(11):1145–52. 10.1080/14656566.2017.1346087.28657473 10.1080/14656566.2017.1346087
33. Anik AH, Proma FA, Saha P et al. Tegoprazan as a new remedy for gastrointestinal diseases in comparison with its therapeutic predecessors: a mini-review. Curr Drug Res Rev 2023; in press. 10.2174/ 2589977515666230428140741.
34. Mermelstein J Mermelstein AC Chait MM Tegoprazan to treat gastroesophageal reflux disease Drugs Today (Barc) 2020 56 11 715 721 10.1358/dot.2020.56.11.3202811 33332479
Mermelstein J, Mermelstein AC, Chait MM. Tegoprazan to treat gastroesophageal reflux disease. Drugs Today (Barc). 2020;56(11):715–21. 10.1358/dot.2020.56.11.3202811.33332479 10.1358/dot.2020.56.11.3202811
35. Ramani A Merchant A Cash BD Review of the clinical development of fexuprazan for gastroesophageal reflux-related disease Eur J Clin Pharmacol 2023 79 8 1023 1029 10.1007/s00228-023-03521-4 37344679
Ramani A, Merchant A, Cash BD. Review of the clinical development of fexuprazan for gastroesophageal reflux-related disease. Eur J Clin Pharmacol. 2023;79(8):1023–9. 10.1007/s00228-023-03521-4.37344679 10.1007/s00228-023-03521-4
36. Kang C Keverprazan Hydrochloride: First Approval Drugs 2023 83 7 639 643 10.1007/s40265-023-01865-w 37074491
Kang C. Keverprazan Hydrochloride: First Approval. Drugs. 2023;83(7):639–43. 10.1007/s40265-023-01865-w.37074491 10.1007/s40265-023-01865-w
37. Sakurai Y Nishimura A Kennedy G Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/non-Japanese subjects Clin Transl Gastroenterol 2015 6 6 e94 10.1038/ctg.2015.18 26111126
Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol. 2015;6(6):e94. 10.1038/ctg.2015.18.26111126 10.1038/ctg.2015.18
38. Jenkins H Sakurai Y Nishimura A Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects Aliment Pharmacol Ther 2015 41 7 636 648 10.1111/apt.13121 25707624
Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41(7):636–48. 10.1111/apt.13121.25707624 10.1111/apt.13121
39. Ohkuma K Iida H Inoh Y Comparison of the early effects of vonoprazan, lansoprazole and famotidine on intragastric pH: a three-way crossover study J Clin Biochem Nutr 2018 63 1 80 83 10.3164/jcbn.17-128 30087548
Ohkuma K, Iida H, Inoh Y, et al. Comparison of the early effects of vonoprazan, lansoprazole and famotidine on intragastric pH: a three-way crossover study. J Clin Biochem Nutr. 2018;63(1):80–3. 10.3164/jcbn.17-128.30087548 10.3164/jcbn.17-128
40. Tansel A, Graham DY. Translating the potency of vonoprazan in the management of acid-related disorders: a systematic review. Gastroenterology. 2023;164(Suppl 1):S588. 10.1016/S0016-5085(23)02370-3.
41. Yuan Y, Hunt RH. Intragastric pH holding time of pH <4 predicts low erosive esophagitis (EE) healing rate. Gastroenterology. 2010;138(Suppl 1):S-651. 10.1016/S0016-5085(10)62998-8.
42. Kagami T Sahara S Ichikawa H Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype Alimentary Pharmacol Therap 2016 43 10 1048 1059 10.1111/apt.13588
Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Alimentary Pharmacol Therap. 2016;43(10):1048–59. 10.1111/apt.13588.10.1111/apt.13588
43. Sakurai Y Mori Y Okamoto H Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects–a randomised open-label cross-over study Aliment Pharmacol Thera 2015 42 6 719 730 10.1111/apt.13325
Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects–a randomised open-label cross-over study. Aliment Pharmacol Thera. 2015;42(6):719–30. 10.1111/apt.13325.10.1111/apt.13325
44. Scarpignato C Leifke E Smith N A population pharmacokinetic model of vonoprazan: evaluating the effects of race, disease status, and other covariates on exposure J Clin Pharmacol 2022 62 6 801 811 10.1002/jcph.2019 34935142
Scarpignato C, Leifke E, Smith N, et al. A population pharmacokinetic model of vonoprazan: evaluating the effects of race, disease status, and other covariates on exposure. J Clin Pharmacol. 2022;62(6):801–11. 10.1002/jcph.2019.34935142 10.1002/jcph.2019
45. Mulford DJ Leifke E Hibberd M The effect of food on the pharmacokinetics of the potassium-competitive acid blocker vonoprazan Clin Pharmacol Drug Dev 2022 11 2 278 284 10.1002/cpdd.1009 34431240
Mulford DJ, Leifke E, Hibberd M, et al. The effect of food on the pharmacokinetics of the potassium-competitive acid blocker vonoprazan. Clin Pharmacol Drug Dev. 2022;11(2):278–84. 10.1002/cpdd.1009.34431240 10.1002/cpdd.1009
46. Wang Y Wang C Wang S Cytochrome P450-based drug-drug interactions of vonoprazan in vitro and in vivo Front Pharmacol 2020 11 53 10.3389/fphar.2020.00053 32116727
Wang Y, Wang C, Wang S, et al. Cytochrome P450-based drug-drug interactions of vonoprazan in vitro and in vivo. Front Pharmacol. 2020;11:53. 10.3389/fphar.2020.00053.32116727 10.3389/fphar.2020.00053
47. Mulford DJ Ramsden D Zhang L Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling CPT Pharmacometrics Syst Pharmacol 2023 12 4 532 544 10.1002/psp4.12939 36896795
Mulford DJ, Ramsden D, Zhang L, et al. Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling. CPT Pharmacometrics Syst Pharmacol. 2023;12(4):532–44. 10.1002/psp4.12939.36896795 10.1002/psp4.12939
48. Zhou S Zhao FL Wang SH Assessments of CYP-inhibition-based drug-drug interaction between vonoprazan and poziotinib in vitro and in vivo Pharm Biol 2023 61 1 356 361 10.1080/13880209.2023.2173253 36728978
Zhou S, Zhao FL, Wang SH, et al. Assessments of CYP-inhibition-based drug-drug interaction between vonoprazan and poziotinib in vitro and in vivo. Pharm Biol. 2023;61(1):356–61. 10.1080/13880209.2023.2173253.36728978 10.1080/13880209.2023.2173253
49. Kagami T Yamade M Suzuki T Comparative study of effects of vonoprazan and esomeprazole on antiplatelet function of clopidogrel or prasugrel in relation to CYP2C19 genotype Clin Pharmacol Ther 2018 103 5 906 913 10.1002/cpt.863 28875498
Kagami T, Yamade M, Suzuki T, et al. Comparative study of effects of vonoprazan and esomeprazole on antiplatelet function of clopidogrel or prasugrel in relation to CYP2C19 genotype. Clin Pharmacol Ther. 2018;103(5):906–13. 10.1002/cpt.863.28875498 10.1002/cpt.863
50. Zvyaga T Chang SY Chen C Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19 Drug Metab Dispos 2012 40 9 1698 1711 10.1124/dmd.112.045575 22648560
Zvyaga T, Chang SY, Chen C, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos. 2012;40(9):1698–711. 10.1124/dmd.112.045575.22648560 10.1124/dmd.112.045575
51. Funakoshi R Tomoda Y Kudo T Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers Br J Clin Pharmacol 2019 85 7 1454 1463 10.1111/bcp.13914 30845361
Funakoshi R, Tomoda Y, Kudo T, et al. Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers. Br J Clin Pharmacol. 2019;85(7):1454–63. 10.1111/bcp.13914.30845361 10.1111/bcp.13914
52. Suzuki Y, Yoshihashi T, Takahashi K, et al. Drug-drug interaction between tacrolimus and vonoprazan in kidney transplant recipients. J Clin Med. 2021;10(17). 10.3390/jcm10173964.
53. Sakurai Y Shiino M Okamoto H Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized Crossover Study Adv Ther 2016 33 9 1519 1535 10.1007/s12325-016-0374-x 27432383
Sakurai Y, Shiino M, Okamoto H, et al. Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized. Crossover Study Adv Ther. 2016;33(9):1519–35. 10.1007/s12325-016-0374-x.27432383 10.1007/s12325-016-0374-x
54. Sakurai Y Shiino M Horii S Pharmacokinetic drug-drug interactions between vonoprazan and low-dose aspirin or nonsteroidal anti-inflammatory drugs: a phase 2, open-label, study in healthy Japanese men Clin Drug Investig 2017 37 1 39 49 10.1007/s40261-016-0455-2 27581248
Sakurai Y, Shiino M, Horii S, et al. Pharmacokinetic drug-drug interactions between vonoprazan and low-dose aspirin or nonsteroidal anti-inflammatory drugs: a phase 2, open-label, study in healthy Japanese men. Clin Drug Investig. 2017;37(1):39–49. 10.1007/s40261-016-0455-2.27581248 10.1007/s40261-016-0455-2
55. Takahashi N Take Y Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility J Pharmacol Exp Ther 2018 364 2 275 286 10.1124/jpet.117.244202 29180359
Takahashi N, Take Y. Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility. J Pharmacol Exp Ther. 2018;364(2):275–86. 10.1124/jpet.117.244202.29180359 10.1124/jpet.117.244202
56. Kim DK Lee KH Kim SJ Effects of tegoprazan, a novel potassium-competitive acid blocker, on rat models of gastric acid-related disease J Pharmacol Exp Ther 2019 369 3 318 327 10.1124/jpet.118.254904 30894456
Kim DK, Lee KH, Kim SJ, et al. Effects of tegoprazan, a novel potassium-competitive acid blocker, on rat models of gastric acid-related disease. J Pharmacol Exp Ther. 2019;369(3):318–27. 10.1124/jpet.118.254904.30894456 10.1124/jpet.118.254904
57. Tajimi M, Nii T, Takahashi N, et al. First-in-human study of the novel acid pump antagonist, RQ-00000004, demonstrated a rapid elevation of gastric pH following single oral administration in healthy subjects. Gastroenterology. 2011;140(5):S80. 10.1016/s0016-5085(11)60324-7.
58. Han S Choi HY Kim YH Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects Alimentary Pharmacol Therap 2019 50 7 751 759 10.1111/apt.15438
Han S, Choi HY, Kim YH, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects. Alimentary Pharmacol Therap. 2019;50(7):751–9. 10.1111/apt.15438.10.1111/apt.15438
59. Han S Choi HY Kim YH Safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating single and multiple oral doses of CJ-12420 (Tegoprazan), a novel potassium-competitive acid blocker (P-CAB) in healthy male subjects Clin Ther 2017 39 8 e97 e98 10.1016/j.clinthera.2017.05.306
Han S, Choi HY, Kim YH, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating single and multiple oral doses of CJ-12420 (Tegoprazan), a novel potassium-competitive acid blocker (P-CAB) in healthy male subjects. Clin Ther. 2017;39(8):e97–8. 10.1016/j.clinthera.2017.05.306.10.1016/j.clinthera.2017.05.306
60. Sunwoo J Ji SC Oh J Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects Aliment Pharmacol Ther 2020 52 11–12 1640 1647 10.1111/apt.16121 33131095
Sunwoo J, Ji SC, Oh J, et al. Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects. Aliment Pharmacol Ther. 2020;52(11–12):1640–7. 10.1111/apt.16121.33131095 10.1111/apt.16121
61. Lee JA Goak IS Lee J Evaluation of the comparative pharmacokinetic properties of a new orally disintegrating tablet of tegoprazan in healthy Korean subjects Int J Clin Pharmacol Ther 2023 61 9 410 420 10.5414/cp204378 37382330
Lee JA, Goak IS, Lee J, et al. Evaluation of the comparative pharmacokinetic properties of a new orally disintegrating tablet of tegoprazan in healthy Korean subjects. Int J Clin Pharmacol Ther. 2023;61(9):410–20. 10.5414/cp204378.37382330 10.5414/cp204378
62. Park S Yang E Kim B Pharmacokinetic and pharmacodynamic exploration of various combinations of tegoprazan immediate and delayed-release formulations Br J Clin Pharmacol 2023 89 9 2877 2887 10.1111/bcp.15784 37170677
Park S, Yang E, Kim B, et al. Pharmacokinetic and pharmacodynamic exploration of various combinations of tegoprazan immediate and delayed-release formulations. Br J Clin Pharmacol. 2023;89(9):2877–87. 10.1111/bcp.15784.37170677 10.1111/bcp.15784
63. Yoon DY Sunwoo J Shin N Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers Clin Transl Sci 2021 14 3 934 941 10.1111/cts.12958 33382926
Yoon DY, Sunwoo J, Shin N, et al. Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers. Clin Transl Sci. 2021;14(3):934–41. 10.1111/cts.12958.33382926 10.1111/cts.12958
64. Han S Choi HY Kim YH Effect of food on the pharmacokinetics and pharmacodynamics of a single oral dose of tegoprazan Clin Ther 2021 43 8 1371 1380 10.1016/j.clinthera.2021.06.007 34246485
Han S, Choi HY, Kim YH, et al. Effect of food on the pharmacokinetics and pharmacodynamics of a single oral dose of tegoprazan. Clin Ther. 2021;43(8):1371–80. 10.1016/j.clinthera.2021.06.007.34246485 10.1016/j.clinthera.2021.06.007
65. Jeong HC, Kim MG, Wei Z et al. Integration of a physiologically based pharmacokinetic and pharmacodynamic model for tegoprazan and its metabolite: application for predicting food effect and intragastric pH alterations. Pharmaceutics. 2022;14(6). 10.3390/pharmaceutics14061298.
66. Oh M Lee H Kim S Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects Transl Clin Pharmacol 2023 31 2 114 123 10.12793/tcp.2023.31.e11 37440779
Oh M, Lee H, Kim S, et al. Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects. Transl Clin Pharmacol. 2023;31(2):114–23. 10.12793/tcp.2023.31.e11.37440779 10.12793/tcp.2023.31.e11
67. Ghim JL Chin MC Jung J Pharmacokinetics and pharmacodynamics of tegoprazan coadministered with amoxicillin and clarithromycin in healthy subjects J Clin Pharmacol 2021 61 7 913 922 10.1002/jcph.1805 33341955
Ghim JL, Chin MC, Jung J, et al. Pharmacokinetics and pharmacodynamics of tegoprazan coadministered with amoxicillin and clarithromycin in healthy subjects. J Clin Pharmacol. 2021;61(7):913–22. 10.1002/jcph.1805.33341955 10.1002/jcph.1805
68. Jeon JY Kim SY Moon SJ Pharmacokinetic interactions between tegoprazan and metronidazole/tetracycline/bismuth and safety assessment in healthy Korean male subjects Clin Ther 2021 43 4 722 734 10.1016/j.clinthera.2021.01.026 33637332
Jeon JY, Kim SY, Moon SJ, et al. Pharmacokinetic interactions between tegoprazan and metronidazole/tetracycline/bismuth and safety assessment in healthy Korean male subjects. Clin Ther. 2021;43(4):722–34. 10.1016/j.clinthera.2021.01.026.33637332 10.1016/j.clinthera.2021.01.026
69. Moon SJ Shin N Kang M Pharmacokinetic interactions between tegoprazan and naproxen, aceclofenac, and celecoxib in healthy Korean male subjects Clin Ther 2022 44 7 930 944 e931 10.1016/j.clinthera.2022.06.002 35787943
Moon SJ, Shin N, Kang M, et al. Pharmacokinetic interactions between tegoprazan and naproxen, aceclofenac, and celecoxib in healthy Korean male subjects. Clin Ther. 2022;44(7):930-944 e931. 10.1016/j.clinthera.2022.06.002.35787943 10.1016/j.clinthera.2022.06.002
70. Li CY, Su M, Yan YY, et al. KFP-H008 blocks gastric acid secretion through inhibiting H+-K+-ATPase. Eur J Pharmacol. 2017;810:112–9. 10.1016/j.ejphar.2017.06.020.
71. Jung JH Lee JH Yoon S-J Pharmacological activities of DWP14012, a novel acid pump antagonist for the treatment of acid-related diseases, including gastroesophageal reflux disease J Neurogastroenterol Motil 2018 24 Suppl 1 S9 S16
Jung JH, Lee JH, Yoon S-J, et al. Pharmacological activities of DWP14012, a novel acid pump antagonist for the treatment of acid-related diseases, including gastroesophageal reflux disease. J Neurogastroenterol Motil. 2018;24(Suppl 1):S9–16.
72. Sunwoo J Oh J Moon SJ Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects Aliment Pharmacol Ther 2018 48 2 206 218 10.1111/apt.14818 29863280
Sunwoo J, Oh J, Moon SJ, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2018;48(2):206–18. 10.1111/apt.14818.29863280 10.1111/apt.14818
73. McGill MR, Jaeschke H. Biomarkers of drug-induced liver injury. Adv Pharmacol. 2019;85:221–39. 10.1016/bs.apha.2019.02.001.
74. Hwang JG Jeon I Park SA Pharmacodynamics and pharmacokinetics of DWP14012 (fexuprazan) in healthy subjects with different ethnicities Aliment Pharmacol Therap 2020 52 11–12 1648 1657 10.1111/apt.16131 33111337
Hwang JG, Jeon I, Park SA, et al. Pharmacodynamics and pharmacokinetics of DWP14012 (fexuprazan) in healthy subjects with different ethnicities. Aliment Pharmacol Therap. 2020;52(11–12):1648–57. 10.1111/apt.16131.33111337 10.1111/apt.16131
75. Jeong YS, Kim MS, Lee N et al. Development of physiologically based pharmacokinetic model for orally administered fexuprazan in humans. Pharmaceutics. 2021;13(6). 10.3390/pharmaceutics13060813.
76. Kim MS, Lee N, Lee A et al. Model-based prediction of acid suppression and proposal of a new dosing regimen of fexuprazan in humans. Pharmaceuticals (Basel). 2022;15(6). 10.3390/ph15060709.
77. Oh J, Yang E, Jang IJ et al. Pharmacodynamic and pharmacokinetic drug interactions between fexuprazan, a novel potassium-competitive inhibitor, and aspirin, in healthy subjects. Pharmaceutics. 2023;15(2). 10.3390/pharmaceutics15020549.
78. Zhou S Xie L Zhou C Keverprazan, a novel potassium-competitive acid blocker: multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects Clin Transl Sci 2023 16 10 1911 1922 10.1111/cts.13598 37533172
Zhou S, Xie L, Zhou C, et al. Keverprazan, a novel potassium-competitive acid blocker: multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects. Clin Transl Sci. 2023;16(10):1911–22. 10.1111/cts.13598.37533172 10.1111/cts.13598
79. Zhou S Xie L Zhou C Keverprazan, a novel potassium-competitive acid blocker: Single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in healthy subjects Eur J Pharm Sci 2023 190 106578 10.1016/j.ejps.2023.106578 37666458
Zhou S, Xie L, Zhou C, et al. Keverprazan, a novel potassium-competitive acid blocker: Single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Eur J Pharm Sci. 2023;190:106578. 10.1016/j.ejps.2023.106578.37666458 10.1016/j.ejps.2023.106578
80. Yang E Kim S Kim B Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole Br J Clin Pharmacol 2022 88 7 3288 3296 10.1111/bcp.15268 35146797
Yang E, Kim S, Kim B, et al. Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. Br J Clin Pharmacol. 2022;88(7):3288–96. 10.1111/bcp.15268.35146797 10.1111/bcp.15268
81. Han S Choi HY Kim YH Comparison of pharmacodynamics between tegoprazan and dexlansoprazole regarding nocturnal acid breakthrough: a randomized crossover study Gut Liver 2023 17 1 92 99 10.5009/gnl220050 36317518
Han S, Choi HY, Kim YH, et al. Comparison of pharmacodynamics between tegoprazan and dexlansoprazole regarding nocturnal acid breakthrough: a randomized crossover study. Gut Liver. 2023;17(1):92–9. 10.5009/gnl220050.36317518 10.5009/gnl220050
82. Zou S Ouyang M Cheng Q Acid-suppressive drugs: a systematic review and network meta-analysis of their nocturnal acid-inhibitory effect Pharmacotherapy 2024 44 2 171 183 10.1002/phar.2899 38049205
Zou S, Ouyang M, Cheng Q, et al. Acid-suppressive drugs: a systematic review and network meta-analysis of their nocturnal acid-inhibitory effect. Pharmacotherapy. 2024;44(2):171–83. 10.1002/phar.2899.38049205 10.1002/phar.2899
83. Hwang S Ko JW Lee H Co-administration of vonoprazan, not tegoprazan, affects the pharmacokinetics of atorvastatin in healthy male subjects Front Pharmacol 2021 12 754849 10.3389/fphar.2021.754849 34867368
Hwang S, Ko JW, Lee H, et al. Co-administration of vonoprazan, not tegoprazan, affects the pharmacokinetics of atorvastatin in healthy male subjects. Front Pharmacol. 2021;12:754849. 10.3389/fphar.2021.754849.34867368 10.3389/fphar.2021.754849
84. Pounder R Smith J Drug-induced changes of plasma gastrin concentration Gastroenterol Clin North Am 1990 19 1 141 153 10.1016/S0889-8553(21)00461-1 2184125
Pounder R, Smith J. Drug-induced changes of plasma gastrin concentration. Gastroenterol Clin North Am. 1990;19(1):141–53.2184125 10.1016/S0889-8553(21)00461-1
85. Di Mario F Ingegnoli A Altavilla N Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels Fundam Clin Pharmacol 2005 19 4 497 501 10.1111/j.1472-8206.2005.00348.x 16011738
Di Mario F, Ingegnoli A, Altavilla N, et al. Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels. Fundam Clin Pharmacol. 2005;19(4):497–501. 10.1111/j.1472-8206.2005.00348.x.16011738 10.1111/j.1472-8206.2005.00348.x
86. Hunt R, Sachs G. A review of the status of omeprazole - the Hanbury workshop. Dig Dis Sci. 1995;40(2):S1–131. 10.1007/Bf02214868.
87. Lundell L Vieth M Gibson F Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology Aliment Pharmacol Ther 2015 42 6 649 663 10.1111/apt.13324 26177572
Lundell L, Vieth M, Gibson F, et al. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015;42(6):649–63. 10.1111/apt.13324.26177572 10.1111/apt.13324
88. Murugesan SV Varro A Pritchard DM Review article: Strategies to determine whether hypergastrinaemia is due to Zollinger-Ellison syndrome rather than a more common benign cause Aliment Pharmacol Ther 2009 29 10 1055 1068 10.1111/j.1365-2036.2009.03976.x 19226290
Murugesan SV, Varro A, Pritchard DM. Review article: Strategies to determine whether hypergastrinaemia is due to Zollinger-Ellison syndrome rather than a more common benign cause. Aliment Pharmacol Ther. 2009;29(10):1055–68. 10.1111/j.1365-2036.2009.03976.x.19226290 10.1111/j.1365-2036.2009.03976.x
89. Hwang I Lee S Editorial: deja vu all over again - let the P-CAB wars begin. Authors' reply Aliment Pharmacol Ther 2023 57 8 914 915 10.1111/apt.17444 36952266
Hwang I, Lee S. Editorial: deja vu all over again - let the P-CAB wars begin. Authors’ reply. Aliment Pharmacol Ther. 2023;57(8):914–5. 10.1111/apt.17444.36952266 10.1111/apt.17444
90. Chiba N De Gara CJ Wilkinson JM Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis Gastroenterology 1997 112 6 1798 1810 10.1053/gast.1997.v112.pm9178669 9178669
Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112(6):1798–810. 10.1053/gast.1997.v112.pm9178669.9178669 10.1053/gast.1997.v112.pm9178669
91. Kang H Kim BJ Choi G Vonoprazan versus proton pump inhibitors for the management of gastroesophageal reflux disease: A protocol for a systematic review with meta-analysis Medicine (Baltimore) 2018 97 39 e12574 10.1097/MD.0000000000012574 30278564
Kang H, Kim BJ, Choi G, et al. Vonoprazan versus proton pump inhibitors for the management of gastroesophageal reflux disease: A protocol for a systematic review with meta-analysis. Medicine (Baltimore). 2018;97(39):e12574. 10.1097/MD.0000000000012574.30278564 10.1097/MD.0000000000012574
92. Cheng Y Liu J Tan X Direct comparison of the efficacy and safety of vonoprazan versus proton-pump inhibitors for gastroesophageal reflux disease: a systematic review and meta-analysis Dig Dis Sci 2021 66 1 19 28 10.1007/s10620-020-06141-5 32095968
Cheng Y, Liu J, Tan X, et al. Direct comparison of the efficacy and safety of vonoprazan versus proton-pump inhibitors for gastroesophageal reflux disease: a systematic review and meta-analysis. Dig Dis Sci. 2021;66(1):19–28. 10.1007/s10620-020-06141-5.32095968 10.1007/s10620-020-06141-5
93. Miyazaki H Igarashi A Takeuchi T Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: a systematic review J Gastroenterol Hepatol 2019 34 8 1316 1328 10.1111/jgh.14664 30883868
Miyazaki H, Igarashi A, Takeuchi T, et al. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: a systematic review. J Gastroenterol Hepatol. 2019;34(8):1316–28. 10.1111/jgh.14664.30883868 10.1111/jgh.14664
94. Zhuang Q Chen S Zhou X Comparative efficacy of P-CAB vs proton pump inhibitors for Grade C/D Esophagitis: a systematic review and network Meta-analysis Ame J Gastroenterol 2024 10.14309/ajg.0000000000002714
Zhuang Q, Chen S, Zhou X, et al. Comparative efficacy of P-CAB vs proton pump inhibitors for Grade C/D Esophagitis: a systematic review and network Meta-analysis. Ame J Gastroenterol. 2024. 10.14309/ajg.0000000000002714.10.14309/ajg.0000000000002714
95. Miwa H Igarashi A Teng L Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease J Gastroenterol 2019 54 8 718 729 10.1007/s00535-019-01572-y 30919071
Miwa H, Igarashi A, Teng L, et al. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease. J Gastroenterol. 2019;54(8):718–29. 10.1007/s00535-019-01572-y.30919071 10.1007/s00535-019-01572-y
96. Xiao Y Zhang S Dai N Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis Gut 2020 69 2 224 230 10.1136/gutjnl-2019-318365 31409606
Xiao Y, Zhang S, Dai N, et al. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut. 2020;69(2):224–30. 10.1136/gutjnl-2019-318365.31409606 10.1136/gutjnl-2019-318365
97. Laine L DeVault K Katz P Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial Gastroenterology 2023 164 1 61 71 10.1053/j.gastro.2022.09.041 36228734
Laine L, DeVault K, Katz P, et al. Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial. Gastroenterology. 2023;164(1):61–71. 10.1053/j.gastro.2022.09.041.36228734 10.1053/j.gastro.2022.09.041
98. Oshima T Arai E Taki M Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis Aliment Pharmacol Therap 2019 49 2 140 146 10.1111/apt.15062 30589965
Oshima T, Arai E, Taki M, et al. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Therap. 2019;49(2):140–6. 10.1111/apt.15062.30589965 10.1111/apt.15062
99. Scarpignato C Howden CW Leifke E A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection Aliment Pharmacol Ther 2023 58 1 16 25 10.1111/apt.17510 37066678
Scarpignato C, Howden CW, Leifke E, et al. A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection. Aliment Pharmacol Ther. 2023;58(1):16–25. 10.1111/apt.17510.37066678 10.1111/apt.17510
100. Fass R Boeckxstaens GE El-Serag H Gastro-oesophageal reflux disease Nat Rev Dis Primers 2021 7 1 55 10.1038/s41572-021-00287-w 34326345
Fass R, Boeckxstaens GE, El-Serag H, et al. Gastro-oesophageal reflux disease. Nat Rev Dis Primers. 2021;7(1):55. 10.1038/s41572-021-00287-w.34326345 10.1038/s41572-021-00287-w
101. Oshima T Igarashi A Nakano H Network Meta-analysis Comparing Vonoprazan and Proton Pump Inhibitors for Heartburn Symptoms in Erosive Esophagitis J Clin Gastroenterol 2022 56 6 493 504 10.1097/MCG.0000000000001707 35470298
Oshima T, Igarashi A, Nakano H, et al. Network Meta-analysis Comparing Vonoprazan and Proton Pump Inhibitors for Heartburn Symptoms in Erosive Esophagitis. J Clin Gastroenterol. 2022;56(6):493–504. 10.1097/MCG.0000000000001707.35470298 10.1097/MCG.0000000000001707
102. Simadibrata DM, Lesmana E, Fass R. A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease. J Gastroenterol Hepatol 2024; in press. 10.1111/jgh.16475.
103. Fass R Vaezi M Sharma P Randomised clinical trial: Efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease Aliment Pharmacol Ther 2023 58 10 1016 1027 10.1111/apt.17728 37750406
Fass R, Vaezi M, Sharma P, et al. Randomised clinical trial: Efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease. Aliment Pharmacol Ther. 2023;58(10):1016–27. 10.1111/apt.17728.37750406 10.1111/apt.17728
104. Fass R Armstrong D Editorial: On-demand vonoprazan for NERD - when should it be 'demanded'? Authors' reply Aliment Pharmacol Ther 2023 58 11–12 1231 10.1111/apt.17766 37986593
Fass R, Armstrong D. Editorial: On-demand vonoprazan for NERD - when should it be “demanded”? Authors’ reply. Aliment Pharmacol Ther. 2023;58(11–12):1231. 10.1111/apt.17766.37986593 10.1111/apt.17766
105. Kawami N Hoshino S Hoshikawa Y Pathogenesis of potassium-competitive acid blocker-resistant non-erosive reflux disease Digestion 2018 98 3 194 200 10.1159/000488530 29870976
Kawami N, Hoshino S, Hoshikawa Y, et al. Pathogenesis of potassium-competitive acid blocker-resistant non-erosive reflux disease. Digestion. 2018;98(3):194–200. 10.1159/000488530.29870976 10.1159/000488530
106. Abe Y Koike T Saito M The Ameliorating Effect of switching to vonoprazan: a novel potassium-competitive acid blocker in patients with proton pump inhibitor refractory non-erosive reflux disease Digestion 2021 102 3 480 488 10.1159/000506152 32062650
Abe Y, Koike T, Saito M, et al. The Ameliorating Effect of switching to vonoprazan: a novel potassium-competitive acid blocker in patients with proton pump inhibitor refractory non-erosive reflux disease. Digestion. 2021;102(3):480–8. 10.1159/000506152.32062650 10.1159/000506152
107. Lee KJ Son BK Kim GH Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis Aliment Pharmacol Ther 2019 49 7 864 872 10.1111/apt.15185 30843245
Lee KJ, Son BK, Kim GH, et al. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019;49(7):864–72. 10.1111/apt.15185.30843245 10.1111/apt.15185
108. Cho YK Kim JH Kim HS Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis Aliment Pharmacol Ther 2023 57 1 72 80 10.1111/apt.17255 36314172
Cho YK, Kim JH, Kim HS, et al. Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis. Aliment Pharmacol Ther. 2023;57(1):72–80. 10.1111/apt.17255.36314172 10.1111/apt.17255
109. Kim SH Cho KB Chun HJ Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease Aliment Pharmacol Therap 2021 54 4 402 411 10.1111/apt.16477 34227708
Kim SH, Cho KB, Chun HJ, et al. Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease. Aliment Pharmacol Therap. 2021;54(4):402–11. 10.1111/apt.16477.34227708 10.1111/apt.16477
110. Scarpignato C Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end! Neurogastroenterol Motil 2012 24 8 697 704 10.1111/j.1365-2982.2012.01977.x 22783985
Scarpignato C. Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end! Neurogastroenterol Motil. 2012;24(8):697–704. 10.1111/j.1365-2982.2012.01977.x.22783985 10.1111/j.1365-2982.2012.01977.x
111. Lee OY, Chun HJ, Kim JJ, et al. A phase 3, non-inferiority randomized controlled trial with Fexuprazan, a novel potassium-competitive acid blocker vs. esomeprazole in patients with erosive esophagitis. Gastroenterology. 2020;158(6):S1072–S1072. 10.1016/S0016-5085(20)33362-X.
112. Zhuang Q Liao A He Q The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double-blind, multicenter study J Gastroenterol Hepatol 2024 39 4 658 666 10.1111/jgh.16471 38251791
Zhuang Q, Liao A, He Q, et al. The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double-blind, multicenter study. J Gastroenterol Hepatol. 2024;39(4):658–66. 10.1111/jgh.16471.38251791 10.1111/jgh.16471
113. Moon SY, Xiao Y. A phase 3, non-inferiority randomized controlled trial with fexuprazan, a novel potassium-competitive acid blocker vs esomeprazole in Chinese patients with erosive esophagitis. Gastroenterology. 2023;164(Suppl):S1303. 10.1016/S0016-5085(23)02358-2.
114. Sung I-K, Lee OY, Choi M-G, et al. Randomized, double-blind, multicenter study to evaluate the efficacy and safety of DPW14012 (fexuprazan) according to the timing of dosing in patients with erosive esophagitis. Gastroenterology. 2023;64(Suppl):S1311. 10.1016/S0016-5085(23)02366-1.
115. Chen S Liu D Chen H The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study Aliment Pharmacol Ther 2022 55 12 1524 1533 10.1111/apt.16959 35505467
Chen S, Liu D, Chen H, et al. The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study. Aliment Pharmacol Ther. 2022;55(12):1524–33. 10.1111/apt.16959.35505467 10.1111/apt.16959
116. Howden CW, Scarpignato C, Leifke E et al. Mathematical model of the relationship between pH holding time and erosive oesophagitis healing rates. Manuscript submitted for publication.
117. Jung HK Tae CH Song KH 2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease J Neurogastroenterol Motil 2021 27 4 453 481 10.5056/jnm21077 34642267
Jung HK, Tae CH, Song KH, et al. 2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2021;27(4):453–81. 10.5056/jnm21077.34642267 10.5056/jnm21077
118. Xiao YL, Zhou LY, Hou XH, et al. Chinese expert consensus on gastroesophageal reflux disease in 2020. J Dig Dis. 2021;22(7):376–89. 10.1111/1751-2980.13028.
119. Iwakiri K Fujiwara Y Manabe N Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021 J Gastroenterol 2022 57 4 267 285 10.1007/s00535-022-01861-z 35226174
Iwakiri K, Fujiwara Y, Manabe N, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol. 2022;57(4):267–85. 10.1007/s00535-022-01861-z.35226174 10.1007/s00535-022-01861-z
120. ValdovinosDíaz MA, Amieva-Balmori M, Carmona-Sánchez R, et al. Good clinical practice recommendations for the diagnosis and treatment of gastroesophageal reflux disease. An expert review from the Asociación Mexicana de Gastroenterología. Rev Gastroenterol Mex (Engl Ed). 2024;89(1):121–43. 10.1016/j.rgmxen.2023.12.002.
121. Scarpignato C Pelosini I Antisecretory drugs for eradication of Helicobacter pylori: antimicrobial activity and synergism with antimicrobial agents Progr Basic Clin Pharmacol 1999 11 135 178
Scarpignato C, Pelosini I. Antisecretory drugs for eradication of Helicobacter pylori: antimicrobial activity and synergism with antimicrobial agents. Progr Basic Clin Pharmacol. 1999;11:135–78.
122. Miehlke S Mannes GA Lehn N An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively Alimet Pharmacol Ther 1997 11 2 323 329 10.1046/j.1365-2036.1997.140316000.x
Miehlke S, Mannes GA, Lehn N, et al. An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. Alimet Pharmacol Ther. 1997;11(2):323–9. 10.1046/j.1365-2036.1997.140316000.x.10.1046/j.1365-2036.1997.140316000.x
123. Kim JI Park SH Kim JK The effects of nocturnal acid breakthrough on Helicobacter pylori eradication Helicobacter 2002 7 6 331 336 10.1046/j.1523-5378.2002.00105.x 12485118
Kim JI, Park SH, Kim JK, et al. The effects of nocturnal acid breakthrough on Helicobacter pylori eradication. Helicobacter. 2002;7(6):331–6. 10.1046/j.1523-5378.2002.00105.x.12485118 10.1046/j.1523-5378.2002.00105.x
124. Sugimoto M Furuta T Shirai N Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy Helicobacter 2007 12 4 317 323 10.1111/j.1523-5378.2007.00508.x 17669104
Sugimoto M, Furuta T, Shirai N, et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter. 2007;12(4):317–23. 10.1111/j.1523-5378.2007.00508.x.17669104 10.1111/j.1523-5378.2007.00508.x
125. Lee JW Kim N Nam RH Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori Gut Liver 2021 15 1 53 60 10.5009/gnl20247 33191308
Lee JW, Kim N, Nam RH, et al. Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori. Gut Liver. 2021;15(1):53–60. 10.5009/gnl20247.33191308 10.5009/gnl20247
126. Dong SQ, Singh TP, Wei X et al. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?. Helicobacter. 2017;22(6). 10.1111/hel.12438.
127. Ahn HJ Kim DP Chu MS Efficacy and safety of the triple therapy containing ilaprazole, levofloxacin, and amoxicillin as first-line treatment in Helicobacter pylori Infections Gastroenterol Res Pract 2017 2017 1654907 10.1155/2017/1654907 28539935
Ahn HJ, Kim DP, Chu MS, et al. Efficacy and safety of the triple therapy containing ilaprazole, levofloxacin, and amoxicillin as first-line treatment in Helicobacter pylori Infections. Gastroenterol Res Pract. 2017;2017:1654907. 10.1155/2017/1654907.28539935 10.1155/2017/1654907
128. Yang C Li S Huang T Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials J Clin Pharm Ther 2022 47 7 897 904 10.1111/jcpt.13637 35247003
Yang C, Li S, Huang T, et al. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials. J Clin Pharm Ther. 2022;47(7):897–904. 10.1111/jcpt.13637.35247003 10.1111/jcpt.13637
129. Sun Y Yue L Hu W Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials Eur J Clin Pharmacol 2023 79 2 279 288 10.1007/s00228-022-03430-y 36527456
Sun Y, Yue L, Hu W. Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials. Eur J Clin Pharmacol. 2023;79(2):279–88. 10.1007/s00228-022-03430-y.36527456 10.1007/s00228-022-03430-y
130. Yang H Zhang M Ma G Meta-analysis of Helicobacter pylori eradication therapy using vonoprazan as an acid suppressor compared with bismuth quadruple therapy Helicobacter 2024 29 2 e13059 10.1111/hel.13059 38443329
Yang H, Zhang M, Ma G, et al. Meta-analysis of Helicobacter pylori eradication therapy using vonoprazan as an acid suppressor compared with bismuth quadruple therapy. Helicobacter. 2024;29(2):e13059. 10.1111/hel.13059.38443329 10.1111/hel.13059
131. Shinozaki S Kobayashi Y Osawa H Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line Helicobacter pylori eradication therapy: systematic review and meta-analysis Digestion 2021 102 3 319 325 10.1159/000504939 31914442
Shinozaki S, Kobayashi Y, Osawa H, et al. Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line Helicobacter pylori eradication therapy: systematic review and meta-analysis. Digestion. 2021;102(3):319–25. 10.1159/000504939.31914442 10.1159/000504939
132. Li M Oshima T Horikawa T Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori Helicobacter 2018 23 4 e12495 10.1111/hel.12495 29873436
Li M, Oshima T, Horikawa T, et al. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Helicobacter. 2018;23(4):e12495. 10.1111/hel.12495.29873436 10.1111/hel.12495
133. Tanabe H Yoshino K Ando K Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication Ann Clin Microbiol Antimicrob 2018 17 1 29 10.1186/s12941-018-0281-x 29950163
Tanabe H, Yoshino K, Ando K, et al. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Ann Clin Microbiol Antimicrob. 2018;17(1):29. 10.1186/s12941-018-0281-x.29950163 10.1186/s12941-018-0281-x
134. Chiba N Hunt RH Drug therapy of Helicobacter pylori Infection: a meta-analysis Prog Basic Clin Pharmacol 1999 11 227 268 10.1159/000061984
Chiba N, Hunt RH. Drug therapy of Helicobacter pylori Infection: a meta-analysis. Prog Basic Clin Pharmacol. 1999;11:227–68.10.1159/000061984
135. Gao CP Zhou Z Wang JZ Efficacy and safety of high-dose dual therapy for Helicobacter pylori rescue therapy: a systematic review and meta-analysis J Dig Dis 2016 17 12 811 819 10.1111/1751-2980.12432 27977071
Gao CP, Zhou Z, Wang JZ, et al. Efficacy and safety of high-dose dual therapy for Helicobacter pylori rescue therapy: a systematic review and meta-analysis. J Dig Dis. 2016;17(12):811–9. 10.1111/1751-2980.12432.27977071 10.1111/1751-2980.12432
136. Yang X Wang JX Han SX High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis Medicine (Baltimore) 2019 98 7 e14396 10.1097/MD.0000000000014396 30762742
Yang X, Wang JX, Han SX, et al. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(7):e14396. 10.1097/MD.0000000000014396.30762742 10.1097/MD.0000000000014396
137. Zhu YJ Zhang Y Wang TY High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis Therap Adv Gastroenterol 2020 13 1756284820937115 10.1177/1756284820937115 33110448
Zhu YJ, Zhang Y, Wang TY, et al. High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis. Therap Adv Gastroenterol. 2020;13:1756284820937115. 10.1177/1756284820937115.33110448 10.1177/1756284820937115
138. Gao CP Zhang D Zhang T PPI-amoxicillin dual therapy for Helicobacter pylori infection: an update based on a systematic review and meta-analysis Helicobacter 2020 25 4 e12692 10.1111/hel.12692 32314468
Gao CP, Zhang D, Zhang T, et al. PPI-amoxicillin dual therapy for Helicobacter pylori infection: an update based on a systematic review and meta-analysis. Helicobacter. 2020;25(4):e12692. 10.1111/hel.12692.32314468 10.1111/hel.12692
139. Xu H Wang W Ma X Comparative efficacy and safety of high-dose dual therapy, bismuth-based quadruple therapy and non-bismuth quadruple therapies for Helicobacter pylori infection: a network meta-analysis Eur J Gastroenterol Hepatol 2021 33 6 775 786 10.1097/meg.0000000000001835 32639419
Xu H, Wang W, Ma X, et al. Comparative efficacy and safety of high-dose dual therapy, bismuth-based quadruple therapy and non-bismuth quadruple therapies for Helicobacter pylori infection: a network meta-analysis. Eur J Gastroenterol Hepatol. 2021;33(6):775–86. 10.1097/meg.0000000000001835.32639419 10.1097/meg.0000000000001835
140. Li C Shi Y Suo B PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: a systematic review and meta-analysis Helicobacter 2021 26 4 e12816 10.1111/hel.12816 34002433
Li C, Shi Y, Suo B, et al. PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: a systematic review and meta-analysis. Helicobacter. 2021;26(4):e12816. 10.1111/hel.12816.34002433 10.1111/hel.12816
141. Zhou BG Mei YZ Jiang X Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: a systematic review and meta-analysis of randomized controlled trials Saudi J Gastroenterol 2023 29 6 347 357 10.4103/sjg.sjg_153_23 37602635
Zhou BG, Mei YZ, Jiang X, et al. Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: a systematic review and meta-analysis of randomized controlled trials. Saudi J Gastroenterol. 2023;29(6):347–57. 10.4103/sjg.sjg_153_23.37602635 10.4103/sjg.sjg_153_23
142. Zhang C Zhang J Cheng YJ High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a meta-analysis of randomized controlled trials Saudi J Gastroenterol 2023 29 2 88 94 10.4103/sjg.sjg_532_22 36960527
Zhang C, Zhang J, Cheng YJ. High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a meta-analysis of randomized controlled trials. Saudi J Gastroenterol. 2023;29(2):88–94. 10.4103/sjg.sjg_532_22.36960527 10.4103/sjg.sjg_532_22
143. Yeh JA, Huang HK, Chou AL et al. Helicobacter pylori eradication with high-dose proton pump inhibitor-amoxicillin dual therapy: a systematic review and meta-analysis. Int J Antimicrob Agents. 2024;107159. 10.1016/j.ijantimicag.2024.107159.
144. Ouyang Y Wang M Xu YL Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis J Gastroenterol Hepatol 2022 37 9 1666 1672 10.1111/jgh.15917 35716370
Ouyang Y, Wang M, Xu YL, et al. Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37(9):1666–72. 10.1111/jgh.15917.35716370 10.1111/jgh.15917
145. Gatta L Scarpignato C Vonopranzan-amoxicillin dual therapy for H pylori infection: a systematic review and meta-analysis UEG J 2020 8 Suppl 250 251
Gatta L, Scarpignato C. Vonopranzan-amoxicillin dual therapy for H pylori infection: a systematic review and meta-analysis. UEG J. 2020;8(Suppl):250–1.
146. Wang Z Wang F Efficacy and safety comparison of Helicobacter pylori eradication between vonoprazan dual therapy versus triple therapy: a systematic review and meta-analysis Therap Adv Gastroenterol 2022 15 17562848221125308 10.1177/17562848221125308 36268270
Wang Z, Wang F. Efficacy and safety comparison of Helicobacter pylori eradication between vonoprazan dual therapy versus triple therapy: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2022;15:17562848221125308. 10.1177/17562848221125308.36268270 10.1177/17562848221125308
147. Zhang WL Lin BS Li YY Efficacy and safety of vonoprazan and amoxicillin dual therapy for Helicobacter pylori eradication: a systematic review and meta-analysis Digestion 2023 104 4 249 261 10.1159/000529622 37015201
Zhang WL, Lin BS, Li YY, et al. Efficacy and safety of vonoprazan and amoxicillin dual therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. Digestion. 2023;104(4):249–61. 10.1159/000529622.37015201 10.1159/000529622
148. Feng JH Cheng J Lao YJ The efficacy and safety of vonoprazan-amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis Eur J Med Res 2023 28 1 272 10.1186/s40001-023-01249-6 37550781
Feng JH, Cheng J, Lao YJ, et al. The efficacy and safety of vonoprazan-amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis. Eur J Med Res. 2023;28(1):272. 10.1186/s40001-023-01249-6.37550781 10.1186/s40001-023-01249-6
149. Du RC Hu YX Ouyang Y Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: A systematic review and meta-analysis Helicobacter 2024 29 1 e13039 10.1111/hel.13039 38036941
Du RC, Hu YX, Ouyang Y, et al. Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: A systematic review and meta-analysis. Helicobacter. 2024;29(1):e13039. 10.1111/hel.13039.38036941 10.1111/hel.13039
150. Zhou BG Jiang X Ding YB Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis Helicobacter 2024 29 1 e13040 10.1111/hel.13040 37983865
Zhou BG, Jiang X, Ding YB, et al. Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. Helicobacter. 2024;29(1):e13040. 10.1111/hel.13040.37983865 10.1111/hel.13040
151. Rokkas T Gisbert JP Malfertheiner P Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori infection: a network meta-analysis Gastroenterology 2021 161 2 495 507.e494 10.1053/j.gastro.2021.04.012 33839101
Rokkas T, Gisbert JP, Malfertheiner P, et al. Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori infection: a network meta-analysis. Gastroenterology. 2021;161(2):495-507.e494. 10.1053/j.gastro.2021.04.012.33839101 10.1053/j.gastro.2021.04.012
152. Li J Shi H Zhou F The efficacy and safety of regimens for Helicobacter pylori eradication treatment in China: a systemic review and network meta-analysis J Clin Gastroenterol 2024 58 1 12 23 10.1097/mcg.0000000000001902 38084866
Li J, Shi H, Zhou F, et al. The efficacy and safety of regimens for Helicobacter pylori eradication treatment in China: a systemic review and network meta-analysis. J Clin Gastroenterol. 2024;58(1):12–23. 10.1097/mcg.0000000000001902.38084866 10.1097/mcg.0000000000001902
153. Gunaratne AW Hamblin H Clancy A Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study Helicobacter 2021 26 5 e12830 10.1111/hel.12830 34247436
Gunaratne AW, Hamblin H, Clancy A, et al. Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study. Helicobacter. 2021;26(5):e12830. 10.1111/hel.12830.34247436 10.1111/hel.12830
154. Chey WD Megraud F Laine L Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial Gastroenterology 2022 163 3 608 619 10.1053/j.gastro.2022.05.055 35679950
Chey WD, Megraud F, Laine L, et al. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology. 2022;163(3):608–19. 10.1053/j.gastro.2022.05.055.35679950 10.1053/j.gastro.2022.05.055
155. Chen PY Tsai FP Chen MJ Vonoprazan-based versus proton pump inhibitor-based therapy in Helicobacter pylori eradication: an updated systematic review and meta-analysis of randomised trials Gut 2024 73 872 874 10.1136/gutjnl-2023-329826 37001979
Chen PY, Tsai FP, Chen MJ, et al. Vonoprazan-based versus proton pump inhibitor-based therapy in Helicobacter pylori eradication: an updated systematic review and meta-analysis of randomised trials. Gut. 2024;73:872–4. 10.1136/gutjnl-2023-329826.37001979 10.1136/gutjnl-2023-329826
156. Graham DY Lu H Shiotani A Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance J Gastroenterol Hepatol 2021 36 5 1159 1163 10.1111/jgh.15252 32918832
Graham DY, Lu H, Shiotani A. Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance. J Gastroenterol Hepatol. 2021;36(5):1159–63. 10.1111/jgh.15252.32918832 10.1111/jgh.15252
157. Ramirez J Guarner F Bustos Fernandez L Antibiotics as major disruptors of gut microbiota Front Cell Infect Microbiol 2020 10 572912 10.3389/fcimb.2020.572912 33330122
Ramirez J, Guarner F, Bustos Fernandez L, et al. Antibiotics as major disruptors of gut microbiota. Front Cell Infect Microbiol. 2020;10:572912. 10.3389/fcimb.2020.572912.33330122 10.3389/fcimb.2020.572912
158. Tao ZH Han JX Fang JY Helicobacter pylori infection and eradication: exploring their impacts on the gastrointestinal microbiota Helicobacter 2020 25 6 e12754 10.1111/hel.12754 32876377
Tao ZH, Han JX, Fang JY. Helicobacter pylori infection and eradication: exploring their impacts on the gastrointestinal microbiota. Helicobacter. 2020;25(6):e12754. 10.1111/hel.12754.32876377 10.1111/hel.12754
159. Horii T Suzuki S Takano C Lower impact of vonoprazan-amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication J Gastroenterol Hepatol 2021 36 12 3314 3321 10.1111/jgh.15572 34107551
Horii T, Suzuki S, Takano C, et al. Lower impact of vonoprazan-amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication. J Gastroenterol Hepatol. 2021;36(12):3314–21. 10.1111/jgh.15572.34107551 10.1111/jgh.15572
160. WHO. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2017;. [https://wwwwhoint/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHOpdf]
161. Choi YJ Lee YC Kim JM Triple therapy-based on Tegoprazan, a new potassium-competitive acid blocker, for first-line treatment of Helicobacter pylori infection: a randomized, double-blind, Phase III Clinical Trial Gut Liver 2022 16 4 535 546 10.5009/gnl220055 35791797
Choi YJ, Lee YC, Kim JM, et al. Triple therapy-based on Tegoprazan, a new potassium-competitive acid blocker, for first-line treatment of Helicobacter pylori infection: a randomized, double-blind, Phase III. Clinical Trial Gut Liver. 2022;16(4):535–46. 10.5009/gnl220055.35791797 10.5009/gnl220055
162. Jung YS Kim S Kim HY 7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: Real-world evidence J Gastroenterol Hepatol 2022 37 10 1911 1918 10.1111/jgh.15939 35816283
Jung YS, Kim S, Kim HY, et al. 7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: Real-world evidence. J Gastroenterol Hepatol. 2022;37(10):1911–8. 10.1111/jgh.15939.35816283 10.1111/jgh.15939
163. Jung YS Kim S Kim HY Efficacy and tolerability of 14-Day Tegoprazan- versus rabeprazole-based triple therapy for eradication of Helicobacter pylori: a real-world evidence study Gut Liver 2023 17 5 711 721 10.5009/gnl220218 36510776
Jung YS, Kim S, Kim HY, et al. Efficacy and tolerability of 14-Day Tegoprazan- versus rabeprazole-based triple therapy for eradication of Helicobacter pylori: a real-world evidence study. Gut Liver. 2023;17(5):711–21. 10.5009/gnl220218.36510776 10.5009/gnl220218
164. Kim JY Lee SY Kim H Efficacy of seven-day potassium-competitive acid blocker-based first-line Helicobacter pylori eradication therapy administered with bismuth Yonsei Med J 2021 62 8 708 716 10.3349/ymj.2021.62.8.708 34296548
Kim JY, Lee SY, Kim H, et al. Efficacy of seven-day potassium-competitive acid blocker-based first-line Helicobacter pylori eradication therapy administered with bismuth. Yonsei Med J. 2021;62(8):708–16. 10.3349/ymj.2021.62.8.708.34296548 10.3349/ymj.2021.62.8.708
165. Cho JH. Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line Helicobacter pylori eradication: a real-world evidence study. Expert Rev Anti Infect Ther. 2024;1–7. 10.1080/14787210.2024.2329251.
166. Kim JS Ko W Chung JW Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: a randomized, double-blind, active-controlled study Helicobacter 2023 28 3 e12977 10.1111/hel.12977 37083222
Kim JS, Ko W, Chung JW, et al. Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: a randomized, double-blind, active-controlled study. Helicobacter. 2023;28(3):e12977. 10.1111/hel.12977.37083222 10.1111/hel.12977
167. Kwon YH Jeon SW Nam SY Ten-day tegoprazan-based concomitant therapy as a first-line treatment for Helicobacter pylori eradication Korean J Intern Med 2023 38 4 493 503 10.3904/kjim.2022.345 37369525
Kwon YH, Jeon SW, Nam SY, et al. Ten-day tegoprazan-based concomitant therapy as a first-line treatment for Helicobacter pylori eradication. Korean J Intern Med. 2023;38(4):493–503. 10.3904/kjim.2022.345.37369525 10.3904/kjim.2022.345
168. Park CH, Song MJ, Jung BW et al. Comparative efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication. J Pers Med. 2022;12(11). 10.3390/jpm12111918.
169. Graham DY Liou JM Primer for development of guidelines for Helicobacter pylori therapy using antimicrobial stewardship Clin Gastroenterol Hepatol 2022 20 5 973 983.e971 10.1016/j.cgh.2021.03.026 33775895
Graham DY, Liou JM. Primer for development of guidelines for Helicobacter pylori therapy using antimicrobial stewardship. Clin Gastroenterol Hepatol. 2022;20(5):973–983.e971. 10.1016/j.cgh.2021.03.026.33775895 10.1016/j.cgh.2021.03.026
170. Lee JH Ahn JY Choi KD Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea: a prospective multicenter study Helicobacter 2019 24 4 e12592 10.1111/hel.12592 31111572
Lee JH, Ahn JY, Choi KD, et al. Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea: a prospective multicenter study. Helicobacter. 2019;24(4):e12592. 10.1111/hel.12592.31111572 10.1111/hel.12592
171. Park JY, Shin TS, Kim JH et al. The Prevalence of Multidrug Resistance of Helicobacter pylori and Its Impact on Eradication in Korea from 2017 to 2019: A Single-Center Study. Antibiotics (Basel). 2020;9(10). 10.3390/ antibiotics9100646.
172. Savoldi A Carrara E Graham DY Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in world health organization Regions Gastroenterology 2018 155 5 1372 1382 e1317 10.1053/j.gastro.2018.07.007 29990487
Savoldi A, Carrara E, Graham DY, et al. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in world health organization Regions. Gastroenterology. 2018;155(5):1372-1382 e1317. 10.1053/j.gastro.2018.07.007.29990487 10.1053/j.gastro.2018.07.007
173. Fallone CA Chiba N van Zanten SV The Toronto consensus for the treatment of Helicobacter pylori infection in adults Gastroenterology 2016 151 1 51 69 e14 10.1053/j.gastro.2016.04.006 27102658
Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51-69 e14. 10.1053/j.gastro.2016.04.006.27102658 10.1053/j.gastro.2016.04.006
174. Malfertheiner P Megraud F Rokkas T Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report Gut 2022 71 1724 1762 10.1136/gutjnl-2022-327745
Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71:1724–62. 10.1136/gutjnl-2022-327745.10.1136/gutjnl-2022-327745
175. Dent J Kahrilas PJ Hatlebakk J A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease Am J Gastroenterol 2008 103 1 20 26 10.1111/j.1572-0241.2007.01544.x 18184117
Dent J, Kahrilas PJ, Hatlebakk J, et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol. 2008;103(1):20–6. 10.1111/j.1572-0241.2007.01544.x.18184117 10.1111/j.1572-0241.2007.01544.x
176. Unge P, Andersson K. Sa1093 - a first-in-human, open-label, healthy volunteer study of the new P-CAN X-832 demonstrating 24h acid control for treatment of acid related diseases. Gastroenterology. 2018;154(6):S-238. 10.1016/s0016-5085(18)31174-0.
177. Sharma P, Vaezi MF, Unge P, et al. Linaprazan glurate is highly effective in treating moderate to severe erosive esophagitis: a double-blind, randomized, dose finding study. UEG J. 2023;11(Suppl):251. 10.1002/ueg2.12460.
178. Sharma P, Vaezi MF, Unge P, et al. Linaprazan glurate is well tolerated in the treatment of patients with erosive esophagitis: a double-blind, randomized, dose finding study. UEG J. 2023;11(Suppl):54. 10.1002/ueg2.12459.
179. Ku JM Cho JH Kim K JP-1366: A novel and potent potassium-competitive acid blocker that is effective in the treatment of acid-related diseases Pharmacol Res Perspect 2023 11 3 e01090 10.1002/prp2.1090 37147903
Ku JM, Cho JH, Kim K, et al. JP-1366: A novel and potent potassium-competitive acid blocker that is effective in the treatment of acid-related diseases. Pharmacol Res Perspect. 2023;11(3):e01090. 10.1002/prp2.1090.37147903 10.1002/prp2.1090
180. Hwang I Ji SC Oh J Randomised clinical trial: Safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in healthy subjects Aliment Pharmacol Ther 2023 57 7 763 772 10.1111/apt.17406 36732884
Hwang I, Ji SC, Oh J, et al. Randomised clinical trial: Safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in healthy subjects. Aliment Pharmacol Ther. 2023;57(7):763–72. 10.1111/apt.17406.36732884 10.1111/apt.17406
181. Hunt RH pH and Hp-gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism Am J Gastroenterol 1993 88 4 481 483 8470623
Hunt RH. pH and Hp-gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism. Am J Gastroenterol. 1993;88(4):481–3.8470623
182. Scarpignato C Pelosini I Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds Ital J Gastroenterol Hepatol 1999 31 Suppl 1 S63 72 10379472
Scarpignato C, Pelosini I. Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds. Ital J Gastroenterol Hepatol. 1999;31(Suppl 1):S63-72.10379472
183. Kawai T Oda K Funao N Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study Gut 2018 67 6 1033 1041 10.1136/gutjnl-2017-314852 29196436
Kawai T, Oda K, Funao N, et al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut. 2018;67(6):1033–41. 10.1136/gutjnl-2017-314852.29196436 10.1136/gutjnl-2017-314852
184. Mizokami Y Oda K Funao N Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study Gut 2018 67 6 1042 1051 10.1136/gutjnl-2017-314010 28988197
Mizokami Y, Oda K, Funao N, et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut. 2018;67(6):1042–51. 10.1136/gutjnl-2017-314010.28988197 10.1136/gutjnl-2017-314010
185. An H Chen J Li S Pantoprazole and vonoprazan performed well in preventing peptic ulcer recurrence in low-dose aspirin users Dig Dis Sci 2024 69 3 670 682 10.1007/s10620-023-08233-4 38252210
An H, Chen J, Li S, et al. Pantoprazole and vonoprazan performed well in preventing peptic ulcer recurrence in low-dose aspirin users. Dig Dis Sci. 2024;69(3):670–82. 10.1007/s10620-023-08233-4.38252210 10.1007/s10620-023-08233-4
186. Asaoka D Nagahara A Hojo M Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia Biomed Rep 2017 6 2 175 180 10.3892/br.2016.828 28357069
Asaoka D, Nagahara A, Hojo M, et al. Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia. Biomed Rep. 2017;6(2):175–80. 10.3892/br.2016.828.28357069 10.3892/br.2016.828
187. Shinozaki S Osawa H Hayashi Y Vonoprazan therapy is as effective for functional dyspepsia without heartburn as acotiamide therapy J Gastrointestin Liver Dis 2023 32 1 23 29 10.15403/jgld-4837 37004225
Shinozaki S, Osawa H, Hayashi Y, et al. Vonoprazan therapy is as effective for functional dyspepsia without heartburn as acotiamide therapy. J Gastrointestin Liver Dis. 2023;32(1):23–9. 10.15403/jgld-4837.37004225 10.15403/jgld-4837
188. Xu W Bai Z Shang Y Incidence and type of adverse events in patients taking vonoprazan: a systematic review and meta-analysis Therap Adv Gastroenterol 2023 16 17562848231167858 10.1177/17562848231167858 37113190
Xu W, Bai Z, Shang Y, et al. Incidence and type of adverse events in patients taking vonoprazan: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2023;16:17562848231167858. 10.1177/17562848231167858.37113190 10.1177/17562848231167858
189. Kinoshita Y Haruma K Yao T Final observation results of VISION trial: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis Gastroenterology 2023 164 Suppl S 1202 10.1016/S0016-5085(23)03775-7
Kinoshita Y, Haruma K, Yao T, et al. Final observation results of VISION trial: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis. Gastroenterology. 2023;164(Suppl):S-1202. 10.1016/S0016-5085(23)03775-7.10.1016/S0016-5085(23)03775-7
